Hope Rugo, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address550 16th. Street
San Francisco CA 94158
Phone415-353-7618
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoPost-Doc Fellow/Scholar1989 Medicine (Cancer Research Institute)
    University of California, San FranciscoResidency School of Medicine
    University of PennsylvaniaM.D.1984School of Medicine

    Collapse Overview 
    Collapse Overview
    Dr. Hope Rugo is a medical oncologist and hematologist specializing in breast cancer research and treatment. A Clinical Professor of Medicine, Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at UCSF in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer. She entered the field of breast cancer in order to incorporate novel therapies based on an understanding of the biology of cancer with excellent quality of care into the treatment of women with breast cancer.

    Dr. Rugo is the Director of the Breast Oncology Clinical Trials Program, and is the principal investigator of multiple clinical trials focusing on combining novel targeted therapeutics with standard treatment to improve the treatment of both early and late stage breast cancer. In addition, Dr. Rugo is working on studies to evaluate cognitive function in women receiving chemotherapy for breast cancer, as well as novel ways to reduce toxicity from therapy. Dr. Rugo has established collaborations with a number of other large academic medical centers for the purpose of expanding the novel therapies that are available for our patients, including herbal agents that appear to have an antitumor effect in the laboratory. She is an active member of the national cooperative group, CALGB, and a is a founding member of the Breast Cancer Research Consortium, as well as serving as an investigator in the UCSF Breast SPORE (the Bay Area Specialized Program of Research Excellence in Breast Cancer). Dr. Rugo teaches medical students and physicians, and regularly lectures locally, nationally and internationally on subjects relating to the treatment of breast cancer. At UCSF, Dr. Rugo runs the Breast Forum, an open bimonthly evening educational session for breast cancer patients, families and friends from throughout the bay area.

    Dr. Rugo graduated from the University of Pennsylvania School of Medicine in 1983. She completed a residency in internal medicine and primary care followed by a fellowship in hematology and oncology at the University of California San Francisco. She was a post-doctoral fellow in immunology participating in laboratory research at Stanford University from 1988-1990. In 1990, Dr. Rugo joined the faculty at UCSF in the Division of Hematology and Oncology. Dr. Rugo has been recognized for her excellence in both patient care and in teaching of both medical students and training physicians. She has received several awards including the Bank of America Gianini Foundation Award and a UCSF Clinical Cancer Center Investigator Research Program intra-mural award. In 2006, she was honored for her work in Breast Cancer Research by the Friends of the Breast Care Center.

    Outside of work, Dr. Rugo spends time with her two children, Philip and Alyssa-Faith, and her husband Martin. Her outside interests include bicycling, hiking, travel with her family and playing the flute.

    Collapse Research 
    Collapse Research Activities and Funding
    General Clinical Research Center
    NIH M01RR000079Dec 1, 1974 - Mar 31, 2009
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Academic Senate

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Sacituzumab Govitecan in Metastatic Breast Cancer. Reply. N Engl J Med. 2021 07 15; 385(3):e12. Bardia A, Hurvitz SA, Rugo HS. PMID: 34260848.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Pembrolizumab plus chemotherapy in triple-negative breast cancer - Authors' reply. Lancet. 2021 07 03; 398(10294):24-25. Cortes J, Rugo HS, Guo Z, Karantza V, Schmid P. PMID: 34217393.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. The evolution of cyclin dependent kinase inhibitors in the treatment of cancer. Expert Rev Anticancer Ther. 2021 Jun 28. Jhaveri K, Burris Rd HA, Yap TA, Hamilton E, Rugo HS, Goldman JW, Dann S, Liu F, Wong GY, Krupka H, Shapiro GI. PMID: 34176404.
      View in: PubMed   Mentions:    Fields:    
    4. Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities. Oncologist. 2021 Jun 27. Spring LM, Nakajima E, Hutchinson J, Viscosi E, Blouin G, Weekes C, Rugo H, Moy B, Bardia A. PMID: 34176192.
      View in: PubMed   Mentions:    Fields:    
    5. RASAL2 confers collateral MEK/EGFR dependency in chemoresistant triple-negative breast cancer. Clin Cancer Res. 2021 Jun 24. Koh SB, Ross K, Isakoff SJ, Melkonjan N, He L, Matissek KJ, Schultz A, Mayer EL, Traina TA, Carey LA, Rugo HS, Liu MC, Stearns V, Langenbucher A, Saladi SV, Ramaswamy S, Lawrence MS, Ellisen LW. PMID: 34168046.
      View in: PubMed   Mentions:    Fields:    
    6. Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2021 Jun 14. Rugo HS, Pennella EJ, Gopalakrishnan U, Hernandez-Bronchud M, Herson J, Koch HF, Loganathan S, Deodhar S, Marwah A, Manikhas A, Bondarenko I, Mukhametshina G, Nemsadze G, Parra JD, Abesamis-Tiambeng MLT, Baramidze K, Akewanlop C, Vynnychenko I, Sriuranpong V, Mamillapalli G, Roy S, Yanez Ruiz EP, Barve A, Fuentes-Alburo A, Waller CF. PMID: 34125340.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Res Treat. 2021 Jun 12. Ruddy KJ, Zheng Y, Tayob N, Hu J, Dang CT, Yardley DA, Isakoff SJ, Valero VV, Faggen MG, Mulvey TM, Bose R, Sella T, Weckstein DJ, Wolff AC, Reeder-Hayes KE, Rugo HS, Ramaswamy B, Zuckerman DS, Hart LL, Gadi VK, Constantine M, Cheng KL, Briccetti FM, Schneider BP, Merrill Garrett A, Kelly Marcom P, Albain KS, DeFusco PA, Tung NM, Ardman BM, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Rosenberg S, DeMeo MK, Burstein HJ, Winer EP, Krop IE, Partridge AH, Tolaney SM. PMID: 34120223.
      View in: PubMed   Mentions:    Fields:    
    8. A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes. Clin Cancer Res. 2021 Jun 09. Potter DA, Thomas A, Rugo HS. PMID: 34108186.
      View in: PubMed   Mentions:    Fields:    
    9. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. J Natl Cancer Inst. 2021 Jun 07. Rugo HS, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Winer EP, Kockx MM, Peeters D, Chui SY, Lin JC, Duc AN, Viale G, Molinero L, Emens LA. PMID: 34097070.
      View in: PubMed   Mentions:    Fields:    
    10. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021 Jun 02. Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. PMID: 34143979.
      View in: PubMed   Mentions:    Fields:    
    11. Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol. 2021 Jun 02; JCO2003398. Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I. PMID: 34077270.
      View in: PubMed   Mentions: 1     Fields:    
    12. Prognostic Factors for Overall Survival in Patients With Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3. Oncologist. 2021 May 26. Rugo HS, Cristofanilli M, Loibl S, Harbeck N, DeMichele A, Iwata H, Park YH, Brufsky A, Theall KP, Huang X, McRoy L, Bananis E, Turner NC. PMID: 34037282.
      View in: PubMed   Mentions:    Fields:    
    13. Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer. Cancers (Basel). 2021 May 08; 13(9). Elghazaly H, Rugo HS, Azim HA, Swain SM, Arun B, Aapro M, Perez EA, Anderson BO, Penault-Llorca F, Conte P, El Saghir NS, Yip CH, Ghosn M, Poortmans P, Shehata MA, Giuliano AE, Leung JWT, Guarneri V, Gligorov J, Gulluoglu BM, Abdel Aziz H, Frolova M, Sabry M, Balch CM, Orecchia R, El-Zawahry HM, Al-Sukhun S, Abdel Karim K, Kandil A, Paltuev RM, Foheidi M, El-Shinawi M, ElMahdy M, Abulkhair O, Yang W, Aref AT, Bakkach J, Bahie Eldin N, Elghazawy H. PMID: 34066769.
      View in: PubMed   Mentions:
    14. NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. J Natl Compr Canc Netw. 2021 05 01; 19(5):484-493. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Matro J, Mayer IA, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns JL, Kumar R. PMID: 34030128.
      View in: PubMed   Mentions: 2     Fields:    
    15. Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer. Breast Cancer Res Treat. 2021 Apr 28. Vidula N, Yau C, Rugo HS. PMID: 33913053.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    16. Effectiveness of Alpelisib + Fulvestrant Compared With Real-World Standard Treatment Among Patients With HR+, HER2-, PIK3CA-Mutated Breast Cancer. Oncologist. 2021 Apr 28. Turner S, Chia S, Kanakamedala H, Hsu WC, Park J, Chandiwana D, Ridolfi A, Yu CL, Zarate JP, Rugo HS. PMID: 33909934.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021 04 22; 384(16):1529-1541. Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS, ASCENT Clinical Trial Investigators . PMID: 33882206.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    18. Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). JNCI Cancer Spectr. 2021 Jun; 5(3):pkab025. Ligibel JA, Huebner L, Rugo HS, Burstein HJ, Toppmeyer DL, Anders CK, Ma C, Barry WT, Suman V, Carey LA, Partridge AH, Hudis CA, Winer EP. PMID: 33981951.
      View in: PubMed   Mentions:
    19. Answers are in the Blood: cfDNA to Enhance Precision Medicine for Breast Cancer. Clin Cancer Res. 2021 Apr 09. Rugo HS, Huppert L. PMID: 33837007.
      View in: PubMed   Mentions:    Fields:    
    20. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. In Reply to Badoui, et al. Oncologist. 2021 Apr 07. Rugo HS, Huober J, Garcia-Saenz JA, Masuda N, Sohn JH, Andre VAM, Barriga S, Cox J, Goetz M. PMID: 33826783.
      View in: PubMed   Mentions:    Fields:    
    21. Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. J Natl Cancer Inst. 2021 Apr 06; 113(4):443-452. Magbanua MJM, Hendrix LH, Hyslop T, Barry WT, Winer EP, Hudis C, Toppmeyer D, Carey LA, Partridge AH, Pierga JY, Fehm T, Vidal-Martínez J, Mavroudis D, Garcia-Saenz JA, Stebbing J, Gazzaniga P, Manso L, Zamarchi R, Antelo ML, Mattos-Arruda L, Generali D, Caldas C, Munzone E, Dirix L, Delson AL, Burstein HJ, Qadir M, Ma C, Scott JH, Bidard FC, Park JW, Rugo HS. PMID: 32770247.
      View in: PubMed   Mentions: 2     Fields:    
    22. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Apr 01; 7(4):573-584. Rugo HS, Im SA, Cardoso F, Cortés J, Curigliano G, Musolino A, Pegram MD, Wright GS, Saura C, Escrivá-de-Romaní S, De Laurentiis M, Levy C, Brown-Glaberman U, Ferrero JM, de Boer M, Kim SB, Petráková K, Yardley DA, Freedman O, Jakobsen EH, Kaufman B, Yerushalmi R, Fasching PA, Nordstrom JL, Bonvini E, Koenig S, Edlich S, Hong S, Rock EP, Gradishar WJ, SOPHIA Study Group . PMID: 33480963.
      View in: PubMed   Mentions: 8     Fields:    
    23. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Apr 01; 7(4):603-608. Filho OM, Stover DG, Asad S, Ansell PJ, Watson M, Loibl S, Geyer CE, Bae J, Collier K, Cherian M, O'Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Maag D, Wolmark N, Denkert C, Symmans WF. PMID: 33599688.
      View in: PubMed   Mentions: 4     Fields:    
    24. Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial. Breast. 2021 Apr 01; 58:18-26. Rugo HS, Pennella EJ, Gopalakrishnan U, Hernandez-Bronchud M, Herson J, Koch HF, Loganathan S, Deodhar S, Marwah A, Manikhas A, Bondarenko I, Parra JD, Abesamis-Tiambeng MLT, Akewanlop C, Vynnychenko I, Sriuranpong V, Roy S, Yanez Ruiz EP, Barve A, Waller CF. PMID: 33892316.
      View in: PubMed   Mentions:    Fields:    
    25. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. J Clin Oncol. 2021 May 10; 39(14):1518-1530. Loibl S, Marmé F, Martin M, Untch M, Bonnefoi H, Kim SB, Bear H, McCarthy N, Melé Olivé M, Gelmon K, García-Sáenz J, Kelly CM, Reimer T, Toi M, Rugo HS, Denkert C, Gnant M, Makris A, Koehler M, Huang-Bartelett C, Lechuga Frean MJ, Colleoni M, Werutsky G, Seiler S, Burchardi N, Nekljudova V, von Minckwitz G. PMID: 33793299.
      View in: PubMed   Mentions: 1     Fields:    
    26. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021 04; 22(4):489-498. Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, Park YH, Prat A, Bachelot T, Juric D, Turner N, Sophos N, Zarate JP, Arce C, Shen YM, Turner S, Kanakamedala H, Hsu WC, Chia S. PMID: 33794206.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    27. Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1. J Clin Oncol. 2021 Mar 29; JCO2001139. Ciruelos EM, Rugo HS, Mayer IA, Levy C, Forget F, Delgado Mingorance JI, Safra T, Masuda N, Park YH, Juric D, Conte P, Campone M, Loibl S, Iwata H, Zhou X, Park J, Ridolfi A, Lorenzo I, André F. PMID: 33780274.
      View in: PubMed   Mentions:    Fields:    
    28. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. Breast Cancer Res. 2021 Mar 24; 23(1):37. DeMichele A, Cristofanilli M, Brufsky A, Liu X, Mardekian J, McRoy L, Layman RM, Emir B, Torres MA, Rugo HS, Finn RS. PMID: 33761995.
      View in: PubMed   Mentions: 1     Fields:    
    29. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1). Clin Cancer Res. 2021 Mar 15. Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley DA, Karuturi M, Sanft T, Blau S, Hart L, Ma C, Rugo HS, Purkayastha D, Moulder S. PMID: 33722897.
      View in: PubMed   Mentions:    Fields:    
    30. An Overview of PARP Inhibitors for the Treatment of Breast Cancer. Target Oncol. 2021 05; 16(3):255-282. Cortesi L, Rugo HS, Jackisch C. PMID: 33710534.
      View in: PubMed   Mentions: 2     Fields:    
    31. Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5?Years of Follow-Up. Oncologist. 2021 May; 26(5):e749-e755. Finn RS, Rugo HS, Gelmon KA, Cristofanilli M, Colleoni M, Loi S, Schnell P, Lu DR, Theall KP, Mori A, Gauthier E, Bananis E, Turner NC, Diéras V. PMID: 33486783.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    32. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. Oncologist. 2021 Mar; 26(3):e522. Rugo HS, Huober J, García-Sáenz JA, Masuda N, Sohn JH, Andre VAM, Barriga S, Cox J, Goetz M. PMID: 33660385.
      View in: PubMed   Mentions:    Fields:    
    33. Navigating a Path to Equity in Cancer Care: The Role of Patient Navigation. Am Soc Clin Oncol Educ Book. 2021 Mar; 41:1-8. Dixit N, Rugo H, Burke NJ. PMID: 33830828.
      View in: PubMed   Mentions:    Fields:    
    34. Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry. Breast Cancer Res Treat. 2021 Jul; 188(1):179-190. Kaufman PA, Hurvitz SA, O'Shaughnessy J, Mason G, Yardley DA, Brufsky AM, Rugo HS, Cobleigh M, Swain SM, Tripathy D, Morris A, Antao V, Li H, Jahanzeb M. PMID: 33641083.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    35. Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer. J Comp Eff Res. 2021 04; 10(6):457-467. Rugo HS, Haltner A, Zhan L, Tran A, Bananis E, Hooper B, Mitra D, Cameron C. PMID: 33626934.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    36. The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+?and androgen receptor-positive metastatic or locally advanced breast cancer. Breast Cancer Res Treat. 2021 May; 187(1):155-165. Wardley A, Cortes J, Provencher L, Miller K, Chien AJ, Rugo HS, Steinberg J, Sugg J, Tudor IC, Huizing M, Young R, Abramson V, Bose R, Hart L, Chan S, Cameron D, Wright GS, Graas MP, Neven P, Rocca A, Russo S, Krop IE. PMID: 33591468.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    37. Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer. Clin Breast Cancer. 2021 Feb 06. Jackisch C, Barcenas CH, Bartsch R, Palma JD, Glück S, Harbeck N, Macedo G, O'Shaughnessy J, Pistilli B, Ruiz-Borrego M, Rugo HS. PMID: 33678567.
      View in: PubMed   Mentions:    Fields:    
    38. Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. JCO Glob Oncol. 2021 02; 7:162-172. Onesti CE, Tagliamento M, Curigliano G, Harbeck N, Bartsch R, Wildiers H, Tjan-Heijnen V, Martin M, Rottey S, Generali D, Campone M, Cristofanilli M, Pusztai L, Peeters M, Berchem G, Cortes J, Ruhstaller T, Ciruelos E, Rugo HS, Jerusalem G. PMID: 33529077.
      View in: PubMed   Mentions:
    39. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. J Natl Cancer Inst. 2021 Feb 01. Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Diéras V, Iwata H, Barrios CH, Nechaeva M, Duc AN, Chui SY, Husain A, Winer EP, Adams S, Schmid P. PMID: 33523233.
      View in: PubMed   Mentions: 7     Fields:    
    40. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021 02; 22(2):212-222. Mayer EL, Dueck AC, Martin M, Rubovszky G, Burstein HJ, Bellet-Ezquerra M, Miller KD, Zdenkowski N, Winer EP, Pfeiler G, Goetz M, Ruiz-Borrego M, Anderson D, Nowecki Z, Loibl S, Moulder S, Ring A, Fitzal F, Traina T, Chan A, Rugo HS, Lemieux J, Henao F, Lyss A, Antolin Novoa S, Wolff AC, Vetter M, Egle D, Morris PG, Mamounas EP, Gil-Gil MJ, Prat A, Fohler H, Metzger Filho O, Schwarz M, DuFrane C, Fumagalli D, Theall KP, Lu DR, Bartlett CH, Koehler M, Fesl C, DeMichele A, Gnant M. PMID: 33460574.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    41. Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum. Lancet Oncol. 2021 01; 22(1):27-28. Dent R, Rugo HS. PMID: 33387495.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    42. Highlights in metastatic breast cancer from the 2020 San Antonio Breast Cancer Symposium: commentary. Clin Adv Hematol Oncol. 2021 Jan; 19 Suppl 1(1):18-19. Rugo HS. PMID: 33843912.
      View in: PubMed   Mentions:    Fields:    
    43. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020 12 05; 396(10265):1817-1828. Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P, KEYNOTE-355 Investigators . PMID: 33278935.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    44. A 4-Month Whole-Systems Ayurvedic Medicine Nutrition and Lifestyle Intervention Is Feasible and Acceptable for Breast Cancer Survivors: Results of a Single-Arm Pilot Clinical Trial. Glob Adv Health Med. 2020; 9:2164956120964712. Dhruva A, Wu C, Miaskowski C, Hartogensis W, Rugo HS, Adler SR, Kaptchuk TJ, Kelkar R, Agarawal S, Vadodaria A, Garris E, Hecht FM. PMID: 33312762.
      View in: PubMed   Mentions:
    45. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. Oncologist. 2021 01; 26(1):e53-e65. Rugo HS, Huober J, García-Sáenz JA, Masuda N, Sohn JH, Andre VAM, Barriga S, Cox J, Goetz M. PMID: 32955138.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    46. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. Clin Breast Cancer. 2021 Feb; 21(1):80-91.e7. Chan A, Moy B, Mansi J, Ejlertsen B, Holmes FA, Chia S, Iwata H, Gnant M, Loibl S, Barrios CH, Somali I, Smichkoska S, Martinez N, Alonso MG, Link JS, Mayer IA, Cold S, Murillo SM, Senecal F, Inoue K, Ruiz-Borrego M, Hui R, Denduluri N, Patt D, Rugo HS, Johnston SRD, Bryce R, Zhang B, Xu F, Wong A, Martin M, ExteNET Study Group . PMID: 33183970.
      View in: PubMed   Mentions: 9     Fields:    
    47. Planning for post-pandemic cancer care delivery: Recovery or opportunity for redesign? CA Cancer J Clin. 2021 01; 71(1):34-46. Cinar P, Bold R, Bosslet BA, Bota DA, Burgess D, Chew HK, Cohen JG, Elquza E, Gold KA, Kamiya E, Karlan BY, McKay RR, Patel SP, Ternavan K, Welborn J, Yamamoto M, Rugo HS. PMID: 32997807.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    48. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 09 01; 6(9):1355-1362. I-SPY2 Trial Consortium , Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Pusztai L, Boughey JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA. PMID: 32701140.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    49. Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic. J Natl Compr Canc Netw. 2020 Sep 01; 1-4. Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Geyer MB, Gojo I, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Lyman GH, Mukherjee S, Perez LE, Rosovsky RP, Roy V, Rugo HS, Vasu S, Wadleigh M, Westervelt P, Becker PS. PMID: 32871558.
      View in: PubMed   Mentions:    Fields:    
    50. Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1. Breast Cancer Res Treat. 2020 Nov; 184(1):161-172. Rugo HS, Dieras V, Cortes J, Patt D, Wildiers H, O'Shaughnessy J, Zamora E, Yardley DA, Carter GC, Sheffield KM, Li L, Andre VAM, Li XI, Frenzel M, Huang YJ, Dickler MN, Tolaney SM. PMID: 32789591.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    51. Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. Breast Cancer Res Treat. 2020 Nov; 184(1):23-35. Finn RS, Cristofanilli M, Ettl J, Gelmon KA, Colleoni M, Giorgetti C, Gauthier E, Liu Y, Lu DR, Zhang Z, Bartlett CH, Slamon DJ, Turner NC, Rugo HS. PMID: 32783178.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    52. Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy. Clin Pharmacol Ther. 2020 09; 108(3):625-634. Chua KC, Xiong C, Ho C, Mushiroda T, Jiang C, Mulkey F, Lai D, Schneider BP, Rashkin SR, Witte JS, Friedman PN, Ratain MJ, McLeod HL, Rugo HS, Shulman LN, Kubo M, Owzar K, Kroetz DL. PMID: 32562552.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    53. Oncological care organisation during COVID-19 outbreak. ESMO Open. 2020 08; 5(4). Onesti CE, Rugo HS, Generali D, Peeters M, Zaman K, Wildiers H, Harbeck N, Martin M, Cristofanilli M, Cortes J, Tjan-Heijnen V, Hurvitz SA, Berchem G, Tagliamento M, Campone M, Bartsch R, De Placido S, Puglisi F, Rottey S, Müller V, Ruhstaller T, Machiels JP, Conte P, Awada A, Jerusalem G. PMID: 32847836.
      View in: PubMed   Mentions:
    54. Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. Nat Commun. 2020 07 17; 11(1):3584. Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME, Rugo H, Rahimi R, Deal T, Daud A, Rosenblum MD, Thomas S, Munster PN. PMID: 32681091.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCellsCTClinical Trials
    55. Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study. J Immunother Cancer. 2020 07; 8(2). Huang CS, Yu AL, Tseng LM, Chow LWC, Hou MF, Hurvitz SA, Schwab RB, L Murray J, Chang HK, Chang HT, Chen SC, Kim SB, Hung JT, Ueng SH, Lee SH, Chen CC, Rugo HS. PMID: 32718986.
      View in: PubMed   Mentions: 1     Fields:    
    56. Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab. Clin Cancer Res. 2020 09 15; 26(18):4911-4920. Magbanua MJM, Savenkov O, Asmus EJ, Ballman KV, Scott JH, Park JW, Dickler M, Partridge A, Carey LA, Winer EP, Rugo HS. PMID: 32586939.
      View in: PubMed   Mentions:    Fields:    
    57. Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting. Clin Cancer Res. 2020 09 15; 26(18):4743-4747. Hafez N, Rugo HS, Tempero MA, Fox E, Reaman GH, Lyerly HK, Walker D, LoRusso PM. PMID: 32571790.
      View in: PubMed   Mentions:    Fields:    
    58. Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. Chin J Cancer Res. 2020 Jun; 32(3):370-382. Li H, Liu R, Shao B, Ran R, Song G, Wang K, Shi Y, Liu J, Hu W, Chen F, Liu X, Zhang G, Zhao C, Jia R, Wang Q, Rugo HS, Zhang Y, Li G, Xu J. PMID: 32694901.
      View in: PubMed   Mentions:
    59. Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib. JCO Precis Oncol. 2020; 4. Batalini F, Moulder SL, Winer EP, Rugo HS, Lin NU, Wulf GM. PMID: 32923889.
      View in: PubMed   Mentions:
    60. The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review. Adv Ther. 2020 07; 37(7):3059-3082. Rugo HS, Jacobs I, Sharma S, Scappaticci F, Paul TA, Jensen-Pergakes K, Malouf GG. PMID: 32445185.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    61. Management of Cancer Cachexia: ASCO Guideline. J Clin Oncol. 2020 07 20; 38(21):2438-2453. Roeland EJ, Bohlke K, Baracos VE, Bruera E, Del Fabbro E, Dixon S, Fallon M, Herrstedt J, Lau H, Platek M, Rugo HS, Schnipper HH, Smith TJ, Tan W, Loprinzi CL. PMID: 32432946.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    62. Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab. Onco Targets Ther. 2020; 13:4385-4395. Ran R, Huang W, Liu Y, Shao L, Liu X, Niu Y, Kong W, Bo S, Rugo HS, Lu S, Li H. PMID: 32547071.
      View in: PubMed   Mentions:
    63. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol. 2020 08; 31(8):1001-1010. Rugo HS, André F, Yamashita T, Cerda H, Toledano I, Stemmer SM, Jurado JC, Juric D, Mayer I, Ciruelos EM, Iwata H, Conte P, Campone M, Wilke C, Mills D, Lteif A, Miller M, Gaudenzi F, Loibl S. PMID: 32416251.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    64. Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633. O'Donnell PH, Trubetskoy V, Nurhussein-Patterson A, Hall JP, Nath A, Huo D, Fleming GF, Ingle JN, Abramson VG, Morrow PK, Storniolo AM, Forero A, Van Poznak C, Liu MC, Chang JC, Merkel DE, Peppercorn JM, Rugo HS, Dees EC, Hahn OM, Hoffman PC, Rosner GL, Huang RS, Ratain MJ, Cox N, Olopade OI, Wolff AC, Dolan ME, Nanda R, Translational Breast Cancer Research Consortium (TBCRC) . PMID: 32378051.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    65. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020 10 15; 147(8):2190-2198. Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, Kelley RK, Ros W, Italiano A, Nakagawa K, Rugo HS, de Braud F, Varga AI, Hansen A, Wang H, Krishnan S, Norwood KG, Doi T. PMID: 32359091.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    66. Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. Am Soc Clin Oncol Educ Book. 2020 May; 40:e292-e308. Gumusay O, Vitiello PP, Wabl C, Corcoran RB, Bardelli A, Rugo HS. PMID: 32453634.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    67. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020 05 01; 6(5):676-684. Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ. PMID: 32053137.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCTClinical Trials
    68. Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival. Breast Cancer Res Treat. 2020 May; 181(1):23-29. Mukhtar RA, Krings G, Chen YY, Mamounas ME, Fahrner-Scott K, Wong J, Alvarado M, Ewing C, Esserman LJ, Rugo H. PMID: 32240457.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    69. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 04; 18(4):452-478. Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Krishnamurthy J, Lyons J, Marcom PK, Matro J, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Young JS, Burns JL, Kumar R. PMID: 32259783.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    70. TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer. Future Oncol. 2020 Apr; 16(12):705-715. Rugo HS, Bardia A, Tolaney SM, Arteaga C, Cortes J, Sohn J, Marmé F, Hong Q, Delaney RJ, Hafeez A, André F, Schmid P. PMID: 32223649.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    71. Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies. Breast Cancer Res. 2020 03 12; 22(1):27. Ettl J, Im SA, Ro J, Masuda N, Colleoni M, Schnell P, Bananis E, Lu DR, Cristofanilli M, Rugo HS, Finn RS. PMID: 32164785.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    72. MYC Dysregulates Mitosis, Revealing Cancer Vulnerabilities. Cell Rep. 2020 03 10; 30(10):3368-3382.e7. Rohrberg J, Van de Mark D, Amouzgar M, Lee JV, Taileb M, Corella A, Kilinc S, Williams J, Jokisch ML, Camarda R, Balakrishnan S, Shankar R, Zhou A, Chang AN, Chen B, Rugo HS, Dumont S, Goga A. PMID: 32160543.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    73. Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial. JAMA Surg. 2020 03 01; 155(3):e195410. Golshan M, Loibl S, Wong SM, Houber JB, O'Shaughnessy J, Rugo HS, Wolmark N, McKee MD, Maag D, Sullivan DM, Metzger-Filho O, Von Minckwitz G, Geyer CE, Sikov WM, Untch M. PMID: 31913413.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    74. Highlights from the 2019 San Antonio Breast Cancer Symposium. Clin Adv Hematol Oncol. 2020 Mar; 18(3):157-159. Rugo HS. PMID: 32609664.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    75. TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer. Breast Cancer Res. 2020 02 18; 22(1):22. Vaklavas C, Roberts BS, Varley KE, Lin NU, Liu MC, Rugo HS, Puhalla S, Nanda R, Storniolo AM, Carey LA, Saleh MN, Li Y, Delossantos JF, Grizzle WE, LoBuglio AF, Myers RM, Forero-Torres A, Translational Breast Cancer Research Consortium (TBCRC) . PMID: 32070401.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsCTClinical Trials
    76. Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars. J Clin Oncol. 2020 04 01; 38(10):1070-1080. Stebbing J, Mainwaring PN, Curigliano G, Pegram M, Latymer M, Bair AH, Rugo HS. PMID: 32058846.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    77. Using diagnosis codes in claims data to identify cohorts of breast cancer patients following initial treatment. Breast J. 2020 07; 26(7):1472-1474. Franc BL, Thombley R, Luo Y, John Boscardin W, Rugo HS, Seidenwurm D, Dudley RA. PMID: 31960541.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    78. Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). Clin Breast Cancer. 2020 06; 20(3):183-193. Kittaneh M, Badve S, Caldera H, Coleman R, Goetz MP, Mahtani R, Mamounas E, Kalinsky K, Lower E, Pegram M, Press MF, Rugo HS, Schwartzberg L, Traina T, Vogel C. PMID: 32014370.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    79. Methylome Variation Predicts Exemestane Resistance in Advanced ER+ Breast Cancer. Technol Cancer Res Treat. 2020 Jan-Dec; 19:1533033819896331. Liu XR, Zhang RY, Gong H, Rugo HS, Chen LB, Fu Y, Che JW, Tie J, Shao B, Wan FL, Kong WY, Song GH, Jiang HF, Xu GB, Li HP. PMID: 32129154.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    80. NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. J Natl Compr Canc Netw. 2020 01; 18(1):12-22. Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Dinner S, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Miller R, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Rosovsky R, Roy V, Rugo HS, Shayani S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Burns J, Keller J, Pluchino LA. PMID: 31910384.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    81. Androgen receptor gene expression in primary breast cancer. NPJ Breast Cancer. 2019; 5:47. Vidula N, Yau C, Wolf D, Rugo HS. PMID: 31840050.
      View in: PubMed   Mentions:
    82. Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance). J Clin Pharmacol. 2020 04; 60(4):444-452. Sharma MR, Mehrotra S, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Velasco M, Overmoyer B, Rugo HS, Ratain MJ, Gobburu JV. PMID: 31802506.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    83. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 01; 21(1):44-59. Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Henschel V, Molinero L, Chui SY, Maiya V, Husain A, Winer EP, Loi S, Emens LA, IMpassion130 Investigators . PMID: 31786121.
      View in: PubMed   Mentions: 122     Fields:    Translation:HumansCTClinical Trials
    84. Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clin Cancer Res. 2020 03 01; 26(5):1105-1113. Cobleigh M, Yardley DA, Brufsky AM, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Hurvitz SA, O'Shaughnessy J, Mason G, Antao V, Li H, Chu L, Jahanzeb M. PMID: 31772121.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    85. Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. Oncologist. 2020 03; 25(3):e439-e450. Hurvitz SA, Gonçalves A, Rugo HS, Lee KH, Fehrenbacher L, Mina LA, Diab S, Blum JL, Chakrabarti J, Elmeliegy M, DeAnnuntis L, Gauthier E, Czibere A, Tudor IC, Quek RGW, Litton JK, Ettl J. PMID: 32162822.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    86. Identifying tests related to breast cancer care in claims data. Breast J. 2020 06; 26(6):1227-1230. Franc BL, Thombley R, Luo Y, Boscardin WJ, Rugo HS, Seidenwurm D, Dudley RA. PMID: 31736191.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    87. Treatment of early-stage hormone receptor-positive breast cancer. Clin Adv Hematol Oncol. 2019 Nov; 17(11):596-599. Rugo HS. PMID: 31851159.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    88. Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy. JNCI Cancer Spectr. 2020 Feb; 4(1):pkz085. Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Mina LA, Diab S, Woodward NE, Yerushalmi R, Goodwin A, Blum JL, Martin M, Quek RGW, Tudor IC, Bhattacharyya H, Gauthier E, Litton JK, Eiermann W. PMID: 32337496.
      View in: PubMed   Mentions:
    89. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. Oncologist. 2020 02; 25(2):e214-e222. Tripathy D, Brufsky A, Cobleigh M, Jahanzeb M, Kaufman PA, Mason G, O'Shaughnessy J, Rugo HS, Swain SM, Yardley DA, Chu L, Li H, Antao V, Hurvitz SA. PMID: 32043771.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    90. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial. Eur J Surg Oncol. 2020 02; 46(2):223-228. Golshan M, Wong SM, Loibl S, Huober JB, O'Shaughnessy J, Rugo HS, Wolmark N, Ansell P, Maag D, Sullivan DM, Metzger-Filho O, Von Minckwitz G, Geyer CE, Sikov WM, Untch M. PMID: 31606288.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    91. Cyclin-dependent kinase 4/6 inhibition in the treatment of hormone receptor-positive breast cancer. Clin Adv Hematol Oncol. 2019 10; 17(10):555-558. Rugo HS. PMID: 31730581.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    92. Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer. Clin Cancer Res. 2020 01 01; 26(1):110-121. Finn RS, Liu Y, Zhu Z, Martin M, Rugo HS, Diéras V, Im SA, Gelmon KA, Harbeck N, Lu DR, Gauthier E, Huang Bartlett C, Slamon DJ. PMID: 31527167.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    93. Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2. Clin Breast Cancer. 2020 04; 20(2):e173-e180. Rugo HS, Finn RS, Gelmon K, Joy AA, Harbeck N, Castrellon A, Mukai H, Walshe JM, Mori A, Gauthier E, Lu DR, Bananis E, Martin M, Diéras V. PMID: 31836434.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    94. Phosphoinositide 3-kinase inhibition in the treatment of hormone receptor-positive breast cancer. Clin Adv Hematol Oncol. 2019 Sep; 17(9):486-489. Rugo HS. PMID: 31549968.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    95. Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Breast J. 2020 03; 26(3):368-375. Gelmon KA, Cristofanilli M, Rugo HS, DeMichele AM, Joy AA, Castrellon A, Sleckman B, Mori A, Theall KP, Lu DR, Huang X, Bananis E, Finn RS, Slamon DJ. PMID: 31448513.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    96. A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer. Clin Breast Cancer. 2020 06; 20(3):e251-e260. Mahtani R, Holmes FA, Badve S, Caldera H, Coleman R, Mamounas E, Kalinsky K, Kittaneh M, Lower E, Pegram M, Press MF, Rugo HS, Schwartzberg L, Vogel C, Breast Cancer Therapy Expert Group (BCTEG) . PMID: 32139271.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    97. Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes. JNCI Cancer Spectr. 2019 Dec; 3(4):pkz058. Uno H, Schrag D, Kim DH, Tang D, Tian L, Rugo HS, Wei LJ. PMID: 32337484.
      View in: PubMed   Mentions:
    98. Achieving Improved Survival Outcomes in Advanced Breast Cancer. N Engl J Med. 2019 07 25; 381(4):371-372. Rugo HS. PMID: 31340099.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    99. Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors. Ther Adv Med Oncol. 2019; 11:1758835919854238. Wesolowski R, Sharma N, Reebel L, Rodal MB, Peck A, West BL, Marimuthu A, Severson P, Karlin DA, Dowlati A, Le MH, Coussens LM, Rugo HS. PMID: 31258629.
      View in: PubMed   Mentions:
    100. Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. Oncologist. 2019 12; 24(12):1514-1525. Diéras V, Harbeck N, Joy AA, Gelmon K, Ettl J, Verma S, Lu DR, Gauthier E, Schnell P, Mori A, Rugo HS, Finn RS. PMID: 31217344.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    101. A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel. NPJ Breast Cancer. 2019; 5:17. Piawah S, Hyland C, Umetsu SE, Esserman LJ, Rugo HS, Chien AJ. PMID: 31240240.
      View in: PubMed   Mentions:
    102. Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease. Breast Cancer Res Treat. 2019 Sep; 177(2):401-408. Melisko ME, Assefa M, Hwang J, DeLuca A, Park JW, Rugo HS. PMID: 31172405.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    103. Fitbit Usage in Patients With Breast Cancer Undergoing Chemotherapy. Clin Breast Cancer. 2019 12; 19(6):443-449.e1. Dreher N, Hadeler EK, Hartman SJ, Wong EC, Acerbi I, Rugo HS, Majure MC, Chien AJ, Esserman LJ, Melisko ME. PMID: 31285177.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    104. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019 05 16; 380(20):1929-1940. André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D, SOLAR-1 Study Group . PMID: 31091374.
      View in: PubMed   Mentions: 313     Fields:    Translation:HumansCTClinical Trials
    105. ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases. Future Oncol. 2019 Jul; 15(19):2211-2225. Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Dieras V, Müller V, Tagliaferri M, Hannah AL, Cortés J. PMID: 31074641.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    106. Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Res Treat. 2019 Jul; 176(2):303-310. Bellon JR, Guo H, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Hudis CA, Krop I, Burstein HJ, Winer EP, Tolaney SM. PMID: 31004299.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    107. Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies. Cancer Med. 2019 05; 8(5):2064-2073. Schwartzberg L, Karthaus M, Rossi G, Rizzi G, Borroni ME, Rugo HS, Jordan K, Hansen V. PMID: 30968588.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    108. Synchronous Breast Implant-associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma: Genomic Profiling and Management Implications. Plast Reconstr Surg Glob Open. 2019 Apr; 7(4):e2188. Mukhtar RA, Holland M, Sieber DA, Wen KW, Rugo HS, Kadin ME, Bean GR. PMID: 31321184.
      View in: PubMed   Mentions:
    109. Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Clin Oncol. 2019 08 01; 37(22):1868-1875. Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay M, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer B, Partridge AH, Hudis CA, Krop IE, Burstein HJ, Winer EP. PMID: 30939096.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    110. Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. J Natl Cancer Inst. 2019 04 01; 111(4):419-430. Diéras V, Rugo HS, Schnell P, Gelmon K, Cristofanilli M, Loi S, Colleoni M, Lu DR, Mori A, Gauthier E, Huang Bartlett C, Slamon DJ, Turner NC, Finn RS. PMID: 30032196.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    111. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019 02 21; 380(8):741-751. Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K. PMID: 30786188.
      View in: PubMed   Mentions: 96     Fields:    Translation:HumansCTClinical Trials
    112. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. J Clin Oncol. 2020 04 01; 38(10):1059-1069. Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, Boughey JC, Elias AD, Haley BB, Kemmer K, Isaacs C, Clark AS, Lang JE, Lu J, Korde L, Edmiston KK, Northfelt DW, Viscusi RK, Yee D, Perlmutter J, Hylton NM, Van't Veer LJ, DeMichele A, Wilson A, Peterson G, Buxton MB, Paoloni M, Clennell J, Berry S, Matthews JB, Steeg K, Singhrao R, Hirst GL, Sanil A, Yau C, Asare SM, Berry DA, Esserman LJ, I-SPY 2 Consortium . PMID: 32031889.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    113. NCCN Guidelines Insights: Breast Cancer, Version 3.2018. J Natl Compr Canc Netw. 2019 02; 17(2):118-126. Goetz MP, Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Farrar WB, Giordano SH, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Telli ML, Ward JH, Young JS, Shead DA, Kumar R. PMID: 30787125.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    114. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial. JAMA Oncol. 2019 02 01; 5(2):e184475. Juric D, Janku F, Rodón J, Burris HA, Mayer IA, Schuler M, Seggewiss-Bernhardt R, Gil-Martin M, Middleton MR, Baselga J, Bootle D, Demanse D, Blumenstein L, Schumacher K, Huang A, Quadt C, Rugo HS. PMID: 30543347.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    115. The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. Breast Cancer Res Treat. 2019 May; 175(1):5-15. Rugo HS, Di Palma JA, Tripathy D, Bryce R, Moran S, Olek E, Bosserman L. PMID: 30671765.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    116. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019 Apr; 174(3):719-729. Rugo HS, Finn RS, Diéras V, Ettl J, Lipatov O, Joy AA, Harbeck N, Castrellon A, Iyer S, Lu DR, Mori A, Gauthier ER, Bartlett CH, Gelmon KA, Slamon DJ. PMID: 30632023.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    117. Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. Clin Cancer Res. 2019 04 15; 25(8):2433-2441. Hurvitz SA, O'Shaughnessy J, Mason G, Yardley DA, Jahanzeb M, Brufsky A, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Chu L, Li H, Antao V, Cobleigh M. PMID: 30593513.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    118. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clin Cancer Res. 2019 05 01; 25(9):2717-2724. Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmaña J, Fasching PA, Hurvitz SA, Wardley AM, Chappey C, Hannah AL, Robson ME, ABRAZO Study Group . PMID: 30563931.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    119. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. J Clin Oncol. 2019 02 01; 37(4):318-327. Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, Rugo HS, Cohen RB, O'Neil BH, Mehnert JM, Lopez J, Doi T, van Brummelen EMJ, Cristescu R, Yang P, Emancipator K, Stein K, Ayers M, Joe AK, Lunceford JK. PMID: 30557521.
      View in: PubMed   Mentions: 144     Fields:    Translation:HumansCellsCTClinical Trials
    120. Demystifying biosimilars: development, regulation and clinical use. Future Oncol. 2019 Mar; 15(7):777-790. Rugo HS, Rifkin RM, Declerck P, Bair AH, Morgan G. PMID: 30500264.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    121. A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance). Clin Pharmacol Ther. 2019 03; 105(3):738-745. Rashkin SR, Chua KC, Ho C, Mulkey F, Jiang C, Mushiroda T, Kubo M, Friedman PN, Rugo HS, McLeod HL, Ratain MJ, Castillos F, Naughton M, Overmoyer B, Toppmeyer D, Witte JS, Owzar K, Kroetz DL. PMID: 30260474.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    122. Geographic and Patient Characteristics Associated With Election of Prophylactic Mastectomy in Young Breast Cancer Patients With Early Disease. Am J Clin Oncol. 2018 Nov; 41(11):1037-1042. Franc BL, Copeland TP, Thombley R, Park M, Marafino B, Dean M, Boscardin WJ, Rugo HS, Dudley RA. PMID: 32463216.
      View in: PubMed   Mentions:    Fields:    
    123. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018 11 29; 379(22):2108-2121. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA, IMpassion130 Trial Investigators . PMID: 30345906.
      View in: PubMed   Mentions: 728     Fields:    Translation:HumansCTClinical Trials
    124. Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer. NPJ Breast Cancer. 2018; 4:31. Magbanua MJM, Rugo HS, Hauranieh L, Roy R, Scott JH, Lee JC, Hsiao F, Sosa EV, Van't Veer L, Esserman LJ, Park JW. PMID: 30211312.
      View in: PubMed   Mentions:
    125. Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer. Am J Cancer Res. 2018; 8(9):1873-1886. Li H, Xu Y, Zhao F, Song G, Rugo HS, Zhang Y, Yang L, Liu X, Shao B, Yang L, Liu Y, Ran R, Zhang R, Guan Y, Chang L, Yi X. PMID: 30323979.
      View in: PubMed   Mentions:
    126. Advance Care Planning in Community: An Evaluation of a Pilot 2-Session, Nurse-Led Workshop. Am J Hosp Palliat Care. 2019 Feb; 36(2):143-146. Rabow MW, McGowan M, Small R, Keyssar R, Rugo HS. PMID: 30153741.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    127. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018 08 23; 379(8):753-763. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. PMID: 30110579.
      View in: PubMed   Mentions: 307     Fields:    Translation:HumansCTClinical Trials
    128. Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials. Clin Breast Cancer. 2018 12; 18(6):489-497. Rugo HS, Roche H, Thomas E, Chung HC, Lerzo GL, Vasyutin I, Patel A, Vahdat L. PMID: 30153978.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    129. Highlights in breast cancer from the 2018 American Society of Clinical Oncology annual meeting. Clin Adv Hematol Oncol. 2018 Aug; 16(8):533-537. Rugo HS. PMID: 30148824.
      View in: PubMed   Mentions:    Fields:    
    130. Circulating Tumors Cells as a Biomarker of Radiation Benefit. JAMA Oncol. 2018 08 01; 4(8):e180194. Speers C, Rugo HS. PMID: 29800965.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    131. Reply to the letter to the editor 'Reporting of HRQoL results from the PALOMA-2 trial: unfounded conclusions due to highly biased analyses' by Kaiser et al. Ann Oncol. 2018 08 01; 29(8):1878. Rugo HS, Iyer S, Huang C. PMID: 29873677.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    132. Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. Eur J Cancer. 2018 09; 101:123-133. Rugo HS, Turner NC, Finn RS, Joy AA, Verma S, Harbeck N, Masuda N, Im SA, Huang X, Kim S, Sun W, Iyer S, Schnell P, Bartlett CH, Johnston S. PMID: 30053671.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    133. The DigniCap Scalp Cooling System and its use in the treatment of chemotherapy-induced alopecia. Future Oncol. 2018 Oct; 14(24):2461-2469. Mustoe MM, Lee CM, Melisko ME, Esserman LJ, Rugo HS. PMID: 30001151.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    134. Geographic Variation in Postoperative Imaging for Low-Risk Breast Cancer. J Natl Compr Canc Netw. 2018 07; 16(7):829-837. Franc BL, Copeland TP, Thombley R, Park M, Marafino B, Dean ML, Boscardin WJ, Rugo HS, Seidenwurm D, Sharma B, Johnston SR, Dudley RA. PMID: 30006425.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    135. Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res. 2018 10 01; 24(19):4734-4744. Li M, Mulkey F, Jiang C, O'Neil BH, Schneider BP, Shen F, Friedman PN, Momozawa Y, Kubo M, Niedzwiecki D, Hochster HS, Lenz HJ, Atkins JN, Rugo HS, Halabi S, Kelly WK, McLeod HL, Innocenti F, Ratain MJ, Venook AP, Owzar K, Kroetz DL. PMID: 29871907.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    136. Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer. Chin J Cancer Res. 2018 Jun; 30(3):315-326. Liu X, Ran R, Shao B, Rugo HS, Yang Y, Hu Z, Wei Z, Wan F, Kong W, Song G, Jiang H, Liang X, Zhang R, Yan Y, Xu G, Li H. PMID: 30046226.
      View in: PubMed   Mentions:
    137. A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. Breast Cancer Res Treat. 2018 Aug; 170(3):547-557. O'Shaughnessy J, DeMichele A, Ma CX, Richards P, Yardley DA, Wright GS, Kalinsky K, Steis R, Diab S, Kennealey G, Geschwindt R, Jiang W, Rugo HS. PMID: 29675680.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    138. The new world of biosimilars in oncology: Translation of data to the clinic. Eur J Cancer. 2018 06; 96:125-127. Rugo HS, Cortes J. PMID: 29680363.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    139. Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol. Clin Cancer Res. 2018 07 15; 24(14):3348-3357. Rugo HS, Cortes J, Awada A, O'Shaughnessy J, Twelves C, Im SA, Hannah A, Lu L, Sy S, Caygill K, Zajchowski DA, Davis DW, Tagliaferri M, Hoch U, Perez EA. PMID: 29618616.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    140. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol. 2018 04 01; 29(4):888-894. Rugo HS, Diéras V, Gelmon KA, Finn RS, Slamon DJ, Martin M, Neven P, Shparyk Y, Mori A, Lu DR, Bhattacharyya H, Bartlett CHUANG, Iyer S, Johnston S, Ettl J, Harbeck N. PMID: 29360932.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    141. Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Clin Cancer Res. 2018 06 15; 24(12):2804-2811. Rugo HS, Delord JP, Im SA, Ott PA, Piha-Paul SA, Bedard PL, Sachdev J, Le Tourneau C, van Brummelen EMJ, Varga A, Salgado R, Loi S, Saraf S, Pietrangelo D, Karantza V, Tan AR. PMID: 29559561.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCellsCTClinical Trials
    142. Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. Anticancer Drugs. 2018 03; 29(3):271-280. Durairaj C, Ruiz-Garcia A, Gauthier ER, Huang X, Lu DR, Hoffman JT, Finn RS, Joy AA, Ettl J, Rugo HS, Zheng J, Wilner KD, Wang DD. PMID: 29360661.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    143. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018 04; 19(4):497-509. Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans WF, Liu X, Geyer CE. PMID: 29501363.
      View in: PubMed   Mentions: 104     Fields:    Translation:HumansCTClinical Trials
    144. Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer. J Am Dent Assoc. 2018 04; 149(4):291-298. Chambers MS, Rugo HS, Litton JK, Meiller TF. PMID: 29439772.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    145. Phosphatidylinositol 3-Kinase a-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. J Clin Oncol. 2018 05 01; 36(13):1291-1299. Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR, Berlin J, Schuler M, Gil-Martin M, Rugo HS, Seggewiss-Bernhardt R, Huang A, Bootle D, Demanse D, Blumenstein L, Coughlin C, Quadt C, Baselga J. PMID: 29401002.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansCTClinical Trials
    146. Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG). Breast Cancer Res Treat. 2018 May; 169(1):1-7. Abraham J, Caldera H, Coleman R, Elias A, Goetz MP, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Rugo H, Schwartzberg L, Traina T, Vogel C. PMID: 29352368.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    147. TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. Cancer Cell. 2018 01 08; 33(1):60-74.e6. de Mingo Pulido Á, Gardner A, Hiebler S, Soliman H, Rugo HS, Krummel MF, Coussens LM, Ruffell B. PMID: 29316433.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansAnimalsCells
    148. Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance). Clin Cancer Res. 2018 03 15; 24(6):1486-1499. Magbanua MJM, Rugo HS, Wolf DM, Hauranieh L, Roy R, Pendyala P, Sosa EV, Scott JH, Lee JS, Pitcher B, Hyslop T, Barry WT, Isakoff SJ, Dickler M, Van't Veer L, Park JW. PMID: 29311117.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    149. Emerging data on improving response to hormone therapy: the role of novel targeted agents. Expert Rev Anticancer Ther. 2018 01; 18(1):3-18. Vidula N, Rugo HS. PMID: 29192520.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    150. Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 12; 15(12):1520-1541. Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I, Griffiths EA, Hough S, Kloth DD, Kuter DJ, Lyman GH, Mably M, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Roy V, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Talbott M, Vadhan-Raj S, Vasu S, Wadleigh M, Westervelt P, Burns JL, Pluchino L. PMID: 29223990.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    151. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. J Clin Oncol. 2017 Dec 20; 35(36):4035-4041. Frenel JS, Le Tourneau C, O'Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, van Brummelen EMJ, Rugo HS, Thomas S, Saraf S, Rangwala R, Varga A. PMID: 29095678.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansCTClinical Trials
    152. Real-world use of scalp cooling to reduce chemotherapy-related hair loss. Clin Adv Hematol Oncol. 2017 Nov; 15(11):828-831. Rugo HS. PMID: 29200414.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    153. Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Res Treat. 2017 11; 166(1):327-328. Cortés J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, O'Shaughnessy J. PMID: 28884461.
      View in: PubMed   Mentions:    Fields:    
    154. Dual HER2 Blockade. Breast Care (Basel). 2017 Oct; 12(5):345-349. Thomssen C, El Saghir NS, Francis PA, Jassem J, Rugo HS, Untch M. PMID: 29234257.
      View in: PubMed   Mentions:
    155. Use of Neoadjuvant Platinum-The Ongoing Conundrum. JAMA Oncol. 2017 10 01; 3(10):1312-1314. Rugo HS, Gelmon K. PMID: 28715579.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    156. Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat. 2018 01; 167(1):117-122. Rice BA, Ver Hoeve ES, DeLuca AN, Esserman LJ, Rugo HS, Melisko ME. PMID: 28921303.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCTClinical Trials
    157. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. NPJ Breast Cancer. 2017; 3:31. Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L. PMID: 28948212.
      View in: PubMed   Mentions:
    158. Quantitative Whole Genome Sequencing of Circulating Tumor Cells Enables Personalized Combination Therapy of Metastatic Cancer. Cancer Res. 2017 08 15; 77(16):4530-4541. Gulbahce N, Magbanua MJM, Chin R, Agarwal MR, Luo X, Liu J, Hayden DM, Mao Q, Ciotlos S, Li Z, Chen Y, Chen X, Li Y, Zhang RY, Lee K, Tearle R, Park E, Drmanac S, Rugo HS, Park JW, Drmanac R, Peters BA. PMID: 28811315.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    159. Scalp Hypothermia for Preventing Alopecia During Chemotherapy. A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clin Breast Cancer. 2018 02; 18(1):19-28. Rugo HS, Voigt J. PMID: 28939291.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    160. Tyrosine Kinase Inhibitors for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Is Personalizing Therapy Within Reach? J Clin Oncol. 2017 09 20; 35(27):3089-3091. Chien AJ, Rugo HS. PMID: 28783451.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    161. Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat. 2017 08; 165(1):161. Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP. PMID: 28660429.
      View in: PubMed   Mentions: 1     Fields:    
    162. Highlights in breast cancer from the 2017 American Society of Clinical Oncology Annual Meeting. Clin Adv Hematol Oncol. 2017 Aug; 15(8):607-614. Rugo HS. PMID: 28949948.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    163. Concerns About Methodology of a Trial Investigating Vaginal Health During Aromatase Inhibitor Therapy for Breast Cancer-Reply. JAMA Oncol. 2017 08 01; 3(8):1142. Melisko ME, Hwang J, Rugo HS. PMID: 28727874.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    164. Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol. 2017 Aug 01; 3(8):1043-1050. Basch E, Dueck AC, Rogak LJ, Minasian LM, Kelly WK, O'Mara AM, Denicoff AM, Seisler D, Atherton PJ, Paskett E, Carey L, Dickler M, Heist RS, Himelstein A, Rugo HS, Sikov WM, Socinski MA, Venook AP, Weckstein DJ, Lake DE, Biggs DD, Freedman RA, Kuzma C, Kirshner JJ, Schrag D. PMID: 28208174.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    165. A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer. Breast Cancer Res Treat. 2017 Oct; 165(3):601-609. Rugo HS, Trédan O, Ro J, Morales SM, Campone M, Musolino A, Afonso N, Ferreira M, Park KH, Cortes J, Tan AR, Blum JL, Eaton L, Gause CK, Wang Z, Im E, Mauro DJ, Jones MB, Denker A, Baselga J. PMID: 28681171.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    166. NCCN Guidelines Insights: Antiemesis, Version 2.2017. J Natl Compr Canc Netw. 2017 07; 15(7):883-893. Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Nabell LM, Noonan K, Roeland E, Rugo HS, Schwartzberg LS, Scullion B, Timoney J, Todaro B, Urba SG, Shead DA, Hughes M. PMID: 28687576.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    167. Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance). AAPS J. 2017 09; 19(5):1411-1423. Mehrotra S, Sharma MR, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Valasco M, Overmoyer B, Rugo H, Ratain MJ, Gobburu JV. PMID: 28620884.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    168. Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Res Treat. 2017 Sep; 165(2):329-341. Cortés J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, O'Shaughnessy J. PMID: 28612225.
      View in: PubMed   Mentions: 12     Fields:    
    169. Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2017 Aug; 165(1):129-138. Vidula N, Yau C, Li J, Esserman LJ, Rugo HS. PMID: 28577080.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    170. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clin Cancer Res. 2017 Sep 01; 23(17):5218-5224. Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J. PMID: 28533223.
      View in: PubMed   Mentions: 126     Fields:    Translation:HumansCTClinical Trials
    171. Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat. 2017 Aug; 165(1):151-159. Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP. PMID: 28503722.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    172. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. J Clin Oncol. 2017 Aug 01; 35(22):2535-2541. Ott PA, Bang YJ, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, Puzanov I, Mehnert JM, Aung KL, Lopez J, Carrigan M, Saraf S, Chen M, Soria JC. PMID: 28489510.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansCTClinical Trials
    173. Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial. Eur J Cancer. 2017 05; 76:205-215. Twelves C, Cortés J, O'Shaughnessy J, Awada A, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Rugo HS. PMID: 28360015.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    174. A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2017 06; 163(3):535-544. Baselga J, Morales SM, Awada A, Blum JL, Tan AR, Ewertz M, Cortes J, Moy B, Ruddy KJ, Haddad T, Ciruelos EM, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Pathiraja K, Gause C, Mauro D, Jones MB, Rugo HS. PMID: 28324268.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    175. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017 05; 18(5):654-662. Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, Dhillon N, Hwang LC, Nangia C, Mayer IA, Meiller TF, Chambers MS, Sweetman RW, Sabo JR, Litton JK. PMID: 28314691.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    176. Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 07 08; 67(4):290-303. Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ, Hortobagyi GN. PMID: 28294295.
      View in: PubMed   Mentions: 156     Fields:    Translation:Humans
    177. Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials. Breast. 2017 Jun; 33:76-82. Rugo HS, Rossi G, Rizzi G, Aapro M. PMID: 28285236.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    178. Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis. Breast Cancer Res Treat. 2017 Jun; 163(2):199-205. Rugo HS, Melin SA, Voigt J. PMID: 28275922.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    179. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2017 Mar 01; 3(3):313-319. Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, Chien AJ, Park JW, Rugo HS. PMID: 27832260.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    180. Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer. JAMA. 2017 02 14; 317(6):606-614. Rugo HS, Klein P, Melin SA, Hurvitz SA, Melisko ME, Moore A, Park G, Mitchel J, Bågeman E, D'Agostino RB, Ver Hoeve ES, Esserman L, Cigler T. PMID: 28196257.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    181. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA. 2017 01 03; 317(1):37-47. Rugo HS, Barve A, Waller CF, Hernandez-Bronchud M, Herson J, Yuan J, Sharma R, Baczkowski M, Kothekar M, Loganathan S, Manikhas A, Bondarenko I, Mukhametshina G, Nemsadze G, Parra JD, Abesamis-Tiambeng ML, Baramidze K, Akewanlop C, Vynnychenko I, Sriuranpong V, Mamillapalli G, Ray S, Yanez Ruiz EP, Pennella E, Heritage Study Investigators . PMID: 27918780.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    182. Strategies and Progress of Endocrine Therapy for Patients with Metastatic Breast Cancer. Adv Exp Med Biol. 2017; 1026:403-418. Rugo HS, Li H, Gui X. PMID: 29282695.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    183. Targeting the host immune system: PD-1 and PD-L1 antibodies and breast cancer. Curr Opin Support Palliat Care. 2016 12; 10(4):336-342. Dawood S, Rugo HS. PMID: 27755140.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    184. NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. Support Care Cancer. 2017 04; 25(4):1127-1135. Aapro M, Karthaus M, Schwartzberg L, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Hansen V, Rossi G, Rizzi G, Borroni ME, Rugo H. PMID: 27885469.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    185. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016 11 17; 375(20):1925-1936. Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ. PMID: 27959613.
      View in: PubMed   Mentions: 471     Fields:    Translation:HumansCTClinical Trials
    186. NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016. J Natl Compr Canc Netw. 2016 11; 14(11):1357-1370. VanderWalde N, Jagsi R, Dotan E, Baumgartner J, Browner IS, Burhenn P, Cohen HJ, Edil BH, Edwards B, Extermann M, Ganti AK, Gross C, Hubbard J, Keating NL, Korc-Grodzicki B, McKoy JM, Medeiros BC, Mrozek E, O'Connor T, Rugo HS, Rupper RW, Shepard D, Silliman RA, Stirewalt DL, Tew WP, Walter LC, Wildes T, Bergman MA, Sundar H, Hurria A. PMID: 27799507.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    187. When to Treat, With What, and for How Long: That Is the Question! J Oncol Pract. 2016 11; 12(11):1160-1162. Dawood S, Rugo HS. PMID: 27858543.
      View in: PubMed   Mentions:    Fields:    
    188. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nat Med. 2016 11; 22(11):1321-1329. Horiuchi D, Camarda R, Zhou AY, Yau C, Momcilovic O, Balakrishnan S, Corella AN, Eyob H, Kessenbrock K, Lawson DA, Marsh LA, Anderton BN, Rohrberg J, Kunder R, Bazarov AV, Yaswen P, McManus MT, Rugo HS, Werb Z, Goga A. PMID: 27775705.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansAnimalsCells
    189. Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial. Springerplus. 2016; 5(1):1033. Cortés J, Rugo HS, Twelves C, Awada A, Perez EA, Im SA, Zhao C, Hoch U, Tomkinson D, Buchanan J, Tagliaferri M, Hannah A, O'Shaughnessy J. PMID: 27441152.
      View in: PubMed   Mentions:
    190. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34. Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ, I-SPY 2 Investigators . PMID: 27406347.
      View in: PubMed   Mentions: 132     Fields:    Translation:HumansCTClinical Trials
    191. Highlights in breast cancer from the 2016 American Society of Clinical Oncology Annual Meeting. Clin Adv Hematol Oncol. 2016 Jul; 14(7):494-7. Rugo HS. PMID: 27379943.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    192. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). Oncologist. 2016 10; 21(10):1165-1175. Verma S, Bartlett CH, Schnell P, DeMichele AM, Loi S, Ro J, Colleoni M, Iwata H, Harbeck N, Cristofanilli M, Zhang K, Thiele A, Turner NC, Rugo HS. PMID: 27368881.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCTClinical Trials
    193. Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. Cancer Med. 2016 08; 5(8):1897-907. Peterson DE, O'Shaughnessy JA, Rugo HS, Elad S, Schubert MM, Viet CT, Campbell-Baird C, Hronek J, Seery V, Divers J, Glaspy J, Schmidt BL, Meiller TF. PMID: 27334013.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    194. Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients. Oncotarget. 2016 Jun 21; 7(25):38359-38366. Morrison G, Lenkala D, LaCroix B, Ziliak D, Abramson V, Morrow PK, Forero A, Van Poznak C, Rugo HS, Nanda R, O'Donnell PH, Huang RS. PMID: 27224917.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    195. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol. 2016 09 01; 34(25):3069-103. Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M, Johnston SR, Korde LA, Khatcheressian JL, Mehta RS, Muss HB, Burstein HJ. PMID: 27217461.
      View in: PubMed   Mentions: 133     Fields:    Translation:Humans
    196. Still Refining Adjuvant Endocrine Therapy in Premenopausal Women: Not Too Much, Not Too Little. J Clin Oncol. 2016 07 01; 34(19):2203-5. Wolff AC, Rugo HS. PMID: 27185850.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    197. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J Clin Oncol. 2016 08 01; 34(22):2602-9. Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, Hudis CA. PMID: 27138575.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    198. A clinician's guide to biosimilars in oncology. Cancer Treat Rev. 2016 May; 46:73-9. Rugo HS, Linton KM, Cervi P, Rosenberg JA, Jacobs I. PMID: 27135548.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    199. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb; 155(3):521-30. Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN. PMID: 26875185.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    200. Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers. Breast Cancer Res Treat. 2016 Feb; 155(3):569-78. Vaz-Luis I, Hughes ME, Cronin A, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU. PMID: 26868124.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    201. HER2-positive breast cancer: is more treatment better? Lancet Oncol. 2016 Mar; 17(3):268-270. Rugo HS, Chien AJ. PMID: 26874902.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    202. Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Ann Oncol. 2016 Mar; 27(3):519-25. Rugo HS, Hortobagyi GN, Yao J, Pavel M, Ravaud A, Franz D, Ringeisen F, Gallo J, Rouyrre N, Anak O, Motzer R. PMID: 26759276.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    203. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncol. 2016 Jan; 2(1):29-36. Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM. PMID: 26539793.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    204. Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options. Am Soc Clin Oncol Educ Book. 2016; 35:e40-54. Rugo HS, Vidula N, Ma C. PMID: 27249746.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    205. Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options. Ther Adv Med Oncol. 2015 Nov; 7(6):321-39. Jiang H, Rugo HS. PMID: 26557900.
      View in: PubMed   Mentions:
    206. Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. Breast Cancer Res Treat. 2015 Nov; 154(2):339-49. Lee JS, Melisko ME, Magbanua MJ, Kablanian AT, Scott JH, Rugo HS, Park JW. PMID: 26520840.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    207. Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. J Clin Oncol. 2016 Feb 10; 34(5):419-26. Hortobagyi GN, Chen D, Piccart M, Rugo HS, Burris HA, Pritchard KI, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband M, Masuda N, Dakhil S, Anderson I, Robinson DM, He W, Garg A, McDonald ER, Bitter H, Huang A, Taran T, Bachelot T, Lebrun F, Lebwohl D, Baselga J. PMID: 26503204.
      View in: PubMed   Mentions: 71     Fields:    Translation:Humans
    208. A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay. PLoS One. 2015; 10(10):e0141166. Magbanua MJ, Pugia M, Lee JS, Jabon M, Wang V, Gubens M, Marfurt K, Pence J, Sidhu H, Uzgiris A, Rugo HS, Park JW. PMID: 26496203.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    209. Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015 Nov; 16(15):1556-1568. Perez EA, Awada A, O'Shaughnessy J, Rugo HS, Twelves C, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Cortes J. PMID: 26482278.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    210. Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer. Clin Breast Cancer. 2016 Feb; 16(1):18-22. Rugo HS. PMID: 26507507.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    211. A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting. Biomed Res Int. 2015; 2015:651879. Hesketh PJ, Aapro M, Jordan K, Schwartzberg L, Bosnjak S, Rugo H. PMID: 26421300.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    212. Cancer-Related Fatigue, Version 2.2015. J Natl Compr Canc Netw. 2015 Aug; 13(8):1012-39. Berger AM, Mooney K, Alvarez-Perez A, Breitbart WS, Carpenter KM, Cella D, Cleeland C, Dotan E, Eisenberger MA, Escalante CP, Jacobsen PB, Jankowski C, LeBlanc T, Ligibel JA, Loggers ET, Mandrell B, Murphy BA, Palesh O, Pirl WF, Plaxe SC, Riba MB, Rugo HS, Salvador C, Wagner LI, Wagner-Johnston ND, Zachariah FJ, Bergman MA, Smith C, National comprehensive cancer network . PMID: 26285247.
      View in: PubMed   Mentions: 127     Fields:    Translation:Humans
    213. Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data. Clin Breast Cancer. 2016 Feb; 16(1):8-17. Vidula N, Rugo HS. PMID: 26303211.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    214. Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. Breast Cancer Res Treat. 2015 Aug; 153(1):173-81. Chien AJ, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, Melisko ME, Esserman LJ, Munster PN, Cedars M, Kerlikowske K, McCulloch CE, Rosen MP. PMID: 26208485.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    215. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. PMID: 26211600.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    216. The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting. Cancer Manag Res. 2015; 7:175-88. Palli SR, Grabner M, Quimbo RA, Rugo HS. PMID: 26124681.
      View in: PubMed   Mentions:
    217. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol. 2015 Jul 20; 33(21):2361-9. Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Leung E, Mayer EL, Naughton M, Toppmeyer D, Carey LA, Perez EA, Hudis C, Winer EP. PMID: 26056183.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCTClinical Trials
    218. Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response. Breast Cancer Res. 2015 May 29; 17:73. Magbanua MJ, Wolf DM, Yau C, Davis SE, Crothers J, Au A, Haqq CM, Livasy C, Rugo HS, I-SPY 1 TRIAL Investigators , Esserman L, Park JW, van 't Veer LJ. PMID: 26021444.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    219. Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Res Treat. 2015 Jun; 151(3):589-96. Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, Krop IE, Burstein HJ, Winer EP, Partridge AH, Tolaney SM. PMID: 25981899.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    220. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2015 Jun 10; 33(17):1902-9. Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW. PMID: 25847936.
      View in: PubMed   Mentions: 117     Fields:    Translation:HumansCTClinical Trials
    221. Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer. Breast Cancer Res Treat. 2015 Apr; 150(3):605-11. Lohmann AE, Chapman JA, Burnell MJ, Levine MN, Tsvetkova E, Pritchard KI, Gelmon KA, O'Brien P, Han L, Rugo HS, Albain KS, Perez EA, Vandenberg TA, Chalchal HI, Sawhney RP, Shepherd LE, Goodwin PJ. PMID: 25833209.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    222. TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2015 Jun 15; 21(12):2722-9. Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ, Krontiras H, De Los Santos JF, Haluska P, Grizzle W, Myers RM, Wolff AC, Translational Breast Cancer Research Consortium (TBCRC) . PMID: 25779953.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    223. Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. Cancer. 2015 Jun 15; 121(12):1937-48. Vaz-Luis I, Hughes ME, Cronin AM, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU. PMID: 25757412.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    224. New and emerging therapeutic options for the management of chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2015 Mar; 13(3 Suppl 3):3-13, 1; quiz 2 p following 14. Schwartzberg LS, Rugo HS, Aapro MS. PMID: 25856052.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    225. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 01; 21(13):2911-5. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. PMID: 25712686.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    226. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015 Jan 08; 372(2):134-41. Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP. PMID: 25564897.
      View in: PubMed   Mentions: 154     Fields:    Translation:HumansCTClinical Trials
    227. Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. Breast Cancer Res Treat. 2015 Jan; 149(2):439-48. Liu S, Chapman JA, Burnell MJ, Levine MN, Pritchard KI, Whelan TJ, Rugo HS, Albain KS, Perez EA, Virk S, Barry G, Gao D, O'Brien P, Shepherd LE, Nielsen TO, Gelmon KA. PMID: 25552364.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    228. Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. J Clin Oncol. 2015 Feb 01; 33(4):340-8. Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, Stockerl-Goldstein K, Neumayer L, Langbaum TS, Theriault RL, Hughes ME, Weeks JC, Karp JE. PMID: 25534386.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    229. Circulating tumor cell analysis in metastatic triple-negative breast cancers. Clin Cancer Res. 2015 Mar 01; 21(5):1098-105. Magbanua MJ, Carey LA, DeLuca A, Hwang J, Scott JH, Rimawi MF, Mayer EL, Marcom PK, Liu MC, Esteva FJ, Park JW, Rugo HS, Translational Breast Cancer Research Consortium . PMID: 25524311.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    230. SIS.NET: a randomized controlled trial evaluating a web-based system for symptom management after treatment of breast cancer. Cancer. 2015 Mar 15; 121(6):893-9. Wheelock AE, Bock MA, Martin EL, Hwang J, Ernest ML, Rugo HS, Esserman LJ, Melisko ME. PMID: 25469673.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    231. Comparative effectiveness analysis of monotherapy with cytotoxic agents in triple-negative metastatic breast cancer in a community setting. Clin Ther. 2015 Jan 01; 37(1):134-44. Dranitsaris G, Gluck S, Faria C, Cox D, Rugo H. PMID: 25433768.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    232. Translating the molecular message of triple-negative breast cancer into targeted therapy. Clin Cancer Res. 2015 Apr 01; 21(7):1511-3. Vidula N, Rugo HS. PMID: 25351747.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    233. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2014 Dec 01; 32(34):3840-7. O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M, Richards P, Specht JM, Yardley DA, Carlson RW, Finn RS, Charpentier E, Garcia-Ribas I, Winer EP. PMID: 25349301.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansCTClinical Trials
    234. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell. 2014 Nov 10; 26(5):623-37. Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CM, Pryer N, Daniel D, Hwang ES, Rugo HS, Coussens LM. PMID: 25446896.
      View in: PubMed   Mentions: 267     Fields:    Translation:HumansAnimalsCells
    235. A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007. Breast Cancer Res Treat. 2014 Nov; 148(1):99-106. Miller KD, Althouse SK, Nabell L, Rugo H, Carey L, Kimmick G, Jones DR, Merino MJ, Steeg PS. PMID: 25257727.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    236. Practice patterns in the delivery of radiation therapy after mastectomy among the University of California Athena Breast Health Network. Clin Breast Cancer. 2015 Feb; 15(1):43-7. Mayadev J, Einck J, Elson S, Rugo H, Hwang S, Bold R, Daroui P, McCloskey S, Yashar C, Kim D, Fowble B. PMID: 25245425.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    237. Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. Int J Hyperthermia. 2014 Aug; 30(5):285-94. Zagar TM, Vujaskovic Z, Formenti S, Rugo H, Muggia F, O'Connor B, Myerson R, Stauffer P, Hsu IC, Diederich C, Straube W, Boss MK, Boico A, Craciunescu O, Maccarini P, Needham D, Borys N, Blackwell KL, Dewhirst MW. PMID: 25144817.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    238. Evidence-driven, patient-specific approaches for optimizing survival prolongation in breast cancer. Clin Adv Hematol Oncol. 2014 Aug; 12(8 Suppl 15):3-21; quiz 22. Gradishar WJ, Twelves C, Rugo HS. PMID: 25768893.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    239. Hormone therapy in premenopausal women with early-stage breast cancer. N Engl J Med. 2014 Jul 10; 371(2):175-6. Rugo HS. PMID: 25006724.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    240. The cancer glycocalyx mechanically primes integrin-mediated growth and survival. Nature. 2014 Jul 17; 511(7509):319-25. Paszek MJ, DuFort CC, Rossier O, Bainer R, Mouw JK, Godula K, Hudak JE, Lakins JN, Wijekoon AC, Cassereau L, Rubashkin MG, Magbanua MJ, Thorn KS, Davidson MW, Rugo HS, Park JW, Hammer DA, Giannone G, Bertozzi CR, Weaver VM. PMID: 25030168.
      View in: PubMed   Mentions: 194     Fields:    Translation:HumansAnimalsCells
    241. Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer. Cancer. 2014 Sep 01; 120(17):2657-64. Kaufman PA, Bloom KJ, Burris H, Gralow JR, Mayer M, Pegram M, Rugo HS, Swain SM, Yardley DA, Chau M, Lalla D, Yoo B, Brammer MG, Vogel CL. PMID: 24930388.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    242. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014 Jul 10; 32(20):2142-50. Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU. PMID: 24888816.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    243. The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. BMC Cancer. 2014 May 02; 14:307. Tripathy D, Rugo HS, Kaufman PA, Swain S, O'Shaughnessy J, Jahanzeb M, Mason G, Beattie M, Yoo B, Lai C, Masaquel A, Hurvitz S. PMID: 24885258.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    244. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. J Clin Oncol. 2014 May 10; 32(14):1472-9. Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM. PMID: 24711549.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    245. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2014 Jun; 145(3):725-34. Yardley DA, Kaufman PA, Brufsky A, Yood MU, Rugo H, Mayer M, Quah C, Yoo B, Tripathy D. PMID: 24706168.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    246. Clinical roundtable monograph: New data in emerging treatment options for chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2014 Mar; 12(3 Suppl 9):1-14; quiz 15. Morrow GR, Navari RM, Rugo HS. PMID: 24874107.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    247. Management of chemotherapy-induced nausea and vomiting in clinical practice. Clin Adv Hematol Oncol. 2014 Mar; 12 Suppl 9(3):9-11. Rugo HS. PMID: 25855943.
      View in: PubMed   Mentions: 1     Fields:    
    248. Senior adult oncology, version 2.2014: clinical practice guidelines in oncology . J Natl Compr Canc Netw. 2014 Jan; 12(1):82-126. Hurria A, Wildes T, Blair SL, Browner IS, Cohen HJ, Deshazo M, Dotan E, Edil BH, Extermann M, Ganti AK, Holmes HM, Jagsi R, Karlekar MB, Keating NL, Korc-Grodzicki B, McKoy JM, Medeiros BC, Mrozek E, O'Connor T, Rugo HS, Rupper RW, Silliman RA, Stirewalt DL, Tew WP, Walter LC, Weir AB, Bergman MA, Sundar H. PMID: 24453295.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    249. Everolimus plus exemestane as first-line therapy in HR?, HER2? advanced breast cancer in BOLERO-2. Breast Cancer Res Treat. 2014 Feb; 143(3):459-67. Beck JT, Hortobagyi GN, Campone M, Lebrun F, Deleu I, Rugo HS, Pistilli B, Masuda N, Hart L, Melichar B, Dakhil S, Geberth M, Nunzi M, Heng DY, Brechenmacher T, El-Hashimy M, Douma S, Ringeisen F, Piccart M. PMID: 24362951.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    250. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer. 2013 Dec; 13(6):421-432.e8. Pritchard KI, Burris HA, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN, Campone M, Csöszi T, Baselga J, Puttawibul P, Piccart M, Heng D, Noguchi S, Srimuninnimit V, Bourgeois H, Gonzalez Martin A, Osborne K, Panneerselvam A, Taran T, Sahmoud T, Gnant M. PMID: 24267730.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    251. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013 Oct; 30(10):870-84. Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS. PMID: 24158787.
      View in: PubMed   Mentions: 144     Fields:    Translation:HumansCTClinical Trials
    252. Myeloid growth factors. J Natl Compr Canc Netw. 2013 Oct 01; 11(10):1266-90. Crawford J, Armitage J, Balducci L, Becker PS, Blayney DW, Cataland SR, Heaney ML, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Steensma DP, Talbott M, Vadhan-Raj S, Westervelt P, Westmoreland M, Dwyer M, Ho M, National comprehensive cancer network . PMID: 24142827.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    253. Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Oct; 141(3):461-70. Rugo HS, Brufsky AM, Ulcickas Yood M, Tripathy D, Kaufman PA, Mayer M, Yoo B, Abidoye OO, Yardley DA. PMID: 24062208.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    254. Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. Curr Med Res Opin. 2013 Nov; 29(11):1463-73. Campone M, Beck JT, Gnant M, Neven P, Pritchard KI, Bachelot T, Provencher L, Rugo HS, Piccart M, Hortobagyi GN, Nunzi M, Heng DY, Baselga J, Komorowski A, Noguchi S, Horiguchi J, Bennett L, Ziemiecki R, Zhang J, Cahana A, Taran T, Sahmoud T, Burris HA. PMID: 23962028.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    255. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res. 2013 Oct 01; 19(19):5505-12. Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA, Translational Breast Cancer Research Consortium (TBCRC 011) . PMID: 23965901.
      View in: PubMed   Mentions: 199     Fields:    Translation:HumansCTClinical Trials
    256. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Eur J Cancer. 2013 Aug; 49(12):2621-32. Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L, Burris HA, Hart L, Melichar B, Hortobagyi GN, Arena F, Baselga J, Panneerselvam A, Héniquez A, El-Hashimyt M, Taran T, Sahmoud T, Piccart M. PMID: 23735704.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    257. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res. 2013 Jul 01; 19(13):3693-702. André F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW, Deudon S, Shi M, Zhang Y, Kay A, Porta DG, Yovine A, Baselga J. PMID: 23658459.
      View in: PubMed   Mentions: 107     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    258. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER. Oncologist. 2013; 18(5):501-10. Tripathy D, Kaufman PA, Brufsky AM, Mayer M, Yood MU, Yoo B, Quah C, Yardley D, Rugo HS. PMID: 23652380.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    259. A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. Breast Cancer Res Treat. 2013 Jun; 139(2):411-9. Rugo HS, Campone M, Amadori D, Aldrighetti D, Conte P, Wardley A, Villanueva C, Melisko M, McHenry MB, Liu D, Lee F, Pivot X. PMID: 23649189.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    260. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer. 2013 May 15; 119(10):1908-15. Burris HA, Lebrun F, Rugo HS, Beck JT, Piccart M, Neven P, Baselga J, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Ricci JF, Bauly H, Taran T, Sahmoud T, Noguchi S. PMID: 23504821.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    261. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013 Jun 01; 19(11):2817-23. DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L. PMID: 23470967.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    262. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clin Cancer Res. 2013 May 15; 19(10):2745-54. Schwartzberg LS, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT, Kaklamani V, Stepanski EJ, Rugo HS, Wang W, Bell-McGuinn K, Kirshner JJ, Eisenberg P, Emanuelson R, Keaton M, Levine E, Medgyesy DC, Qamar R, Starr A, Ro SK, Lokker NA, Hudis CA. PMID: 23444220.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    263. Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. J Natl Cancer Inst. 2013 May 01; 105(9):654-63. Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI. PMID: 23425564.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    264. Emerging treatments in chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2013 Feb; 11(2 Suppl 1):1-18; quiz 2 p following 18. Grunberg SM, Slusher B, Rugo HS. PMID: 23598819.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    265. New developments in metastatic breast cancer: general discussion. Clin Adv Hematol Oncol. 2013; 11(10 Suppl 16):16-7. Vahdat LT, Rugo HS, Perez EA. PMID: 24765684.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    266. New developments in metastatic breast cancer: integrating recent data into clinical practice. Clin Adv Hematol Oncol. 2013; 11(10 Suppl 16):1-18; quiz 19. Perez EA, Rugo HS, Vahdat LT. PMID: 24892840.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    267. New developments in metastatic breast cancer: introduction. Clin Adv Hematol Oncol. 2013; 11(10 Suppl 16):4-7. Rugo HS. PMID: 24637554.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    268. Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. J Natl Cancer Inst. 2013 Jan 16; 105(2):104-12. Vandergrift JL, Niland JC, Theriault RL, Edge SB, Wong YN, Loftus LS, Breslin TM, Hudis CA, Javid SH, Rugo HS, Silver SM, Lepisto EM, Weeks JC. PMID: 23264681.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    269. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol. 2012 Dec 20; 30(36):4584-6; author reply 4588-9. Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L. PMID: 23169510.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    270. Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(1):1-12. Chien AJ, Rugo HS. PMID: 23143215.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    271. Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Res. 2013 Jan 01; 73(1):30-40. Magbanua MJ, Sosa EV, Roy R, Eisenbud LE, Scott JH, Olshen A, Pinkel D, Rugo HS, Park JW. PMID: 23135909.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    272. Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer. Future Oncol. 2012 Nov; 8(11):1383-96. Keck S, Glencer AC, Rugo HS. PMID: 23148612.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    273. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res. 2012 Oct 01; 14(5):R129. Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS, Theriault RL, Wilson J, Niland JC, Weeks JC, Lin NU. PMID: 23025714.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    274. Progress against solid tumors in danger: the metastatic breast cancer example. J Clin Oncol. 2012 Oct 01; 30(28):3444-7. Cortés J, Calvo E, González-Martín A, Dawood S, Llombart-Cussac A, De Mattos-Arruda L, Gómez P, Silva O, Perez EA, Rugo HS, Lluch A, Hortobagyi GN. PMID: 22927522.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    275. Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Cancer Res Treat. 2012 Oct; 135(3):875-83. Kaufman PA, Brufsky AM, Mayer M, Rugo HS, Tripathy D, Yood MU, Feng S, Wang LI, Quah CS, Yardley DA. PMID: 22923238.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    276. A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol. 2012 Oct; 70(4):591-601. Bender BC, Schaedeli-Stark F, Koch R, Joshi A, Chu YW, Rugo H, Krop IE, Girish S, Friberg LE, Gupta M. PMID: 22886072.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    277. The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors. Breast Cancer Res Treat. 2012 Aug; 134(3):1327-35. Bock M, Moore D, Hwang J, Shumay D, Lawson L, Hamolsky D, Esserman L, Rugo H, Chien AJ, Park J, Munster P, Melisko M. PMID: 22798157.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    278. Patient perceptions of reproductive health counseling at the time of cancer diagnosis: a qualitative study of female California cancer survivors. J Cancer Surviv. 2012 Sep; 6(3):324-32. Niemasik EE, Letourneau J, Dohan D, Katz A, Melisko M, Rugo H, Rosen M. PMID: 22752834.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    279. Reversing hormone resistance: have we found the golden key? J Clin Oncol. 2012 Aug 01; 30(22):2707-9. Rugo HS, Keck S. PMID: 22753913.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    280. The role of targeted therapy and biomarkers in breast cancer treatment. Clin Exp Metastasis. 2012 Oct; 29(7):807-19. Stopeck AT, Brown-Glaberman U, Wong HY, Park BH, Barnato SE, Gradishar WJ, Hudis CA, Rugo HS. PMID: 22692561.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    281. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012 Jul 20; 30(21):2585-92. Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J. PMID: 22689807.
      View in: PubMed   Mentions: 176     Fields:    Translation:HumansCTClinical Trials
    282. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012 Jul 20; 30(21):2615-23. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP. PMID: 22665533.
      View in: PubMed   Mentions: 191     Fields:    Translation:HumansCellsCTClinical Trials
    283. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012 Sep 10; 30(26):3242-9. Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N. PMID: 22649152.
      View in: PubMed   Mentions: 148     Fields:    Translation:Humans
    284. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2012 Sep 10; 30(26):3234-41. Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS. PMID: 22649126.
      View in: PubMed   Mentions: 89     Fields:    Translation:HumansCTClinical Trials
    285. The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. Cancer Discov. 2012 Jul; 2(7):638-51. Littlepage LE, Adler AS, Kouros-Mehr H, Huang G, Chou J, Krig SR, Griffith OL, Korkola JE, Qu K, Lawson DA, Xue Q, Sternlicht MD, Dijkgraaf GJ, Yaswen P, Rugo HS, Sweeney CA, Collins CC, Gray JW, Chang HY, Werb Z. PMID: 22728437.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    286. Associations between pro- and anti-inflammatory cytokine genes and breast pain in women prior to breast cancer surgery. J Pain. 2012 May; 13(5):425-37. McCann B, Miaskowski C, Koetters T, Baggott C, West C, Levine JD, Elboim C, Abrams G, Hamolsky D, Dunn L, Rugo H, Dodd M, Paul SM, Neuhaus J, Cooper B, Schmidt B, Langford D, Cataldo J, Aouizerat BE. PMID: 22515947.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    287. Antiemesis. J Natl Compr Canc Netw. 2012 Apr; 10(4):456-85. Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Michaud LB, Nabati L, Noonan K, Rugo HS, Siler D, Sorscher SM, Stelts S, Stucky-Marshall L, Todaro B, Urba SG, National Comprehensive Cancer Network . PMID: 22491046.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    288. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat. 2012 Jun; 133(3):1067-75. Brufsky A, Valero V, Tiangco B, Dakhil S, Brize A, Rugo HS, Rivera R, Duenne A, Bousfoul N, Yardley DA. PMID: 22415477.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    289. Inhibiting angiogenesis in breast cancer: the beginning of the end or the end of the beginning? J Clin Oncol. 2012 Mar 20; 30(9):898-901. Rugo HS. PMID: 22331930.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    290. Senior adult oncology. J Natl Compr Canc Netw. 2012 Feb; 10(2):162-209. Hurria A, Browner IS, Cohen HJ, Denlinger CS, deShazo M, Extermann M, Ganti AK, Holland JC, Holmes HM, Karlekar MB, Keating NL, McKoy J, Medeiros BC, Mrozek E, O'Connor T, Petersdorf SH, Rugo HS, Silliman RA, Tew WP, Walter LC, Weir AB, Wildes T. PMID: 22308515.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    291. An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer. Cancer. 2012 Sep 01; 118(17):4098-104. Morrow PK, Murthy RK, Ensor JD, Gordon GS, Margolin KA, Elias AD, Urba WJ, Weng DE, Rugo HS, Hortobagyi GN. PMID: 22281842.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    292. Neoadjuvant therapy for HER2-positive early-stage breast cancer: the future is almost here. Oncology (Williston Park). 2012 Jan; 26(1):26, 28-9. Rugo HS. PMID: 22393793.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    293. Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat. 2012 Apr; 132(3):1107-18. Lorizio W, Wu AH, Beattie MS, Rugo H, Tchu S, Kerlikowske K, Ziv E. PMID: 22207277.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    294. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012 Apr; 132(3):1049-62. Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N, I-SPY 1 TRIAL Investigators . PMID: 22198468.
      View in: PubMed   Mentions: 149     Fields:    Translation:Humans
    295. A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2012 Jul; 134(1):13-20. Rugo HS, Chien AJ, Franco SX, Stopeck AT, Glencer A, Lahiri S, Arbushites MC, Scott J, Park JW, Hudis C, Nulsen B, Dickler MN. PMID: 22198412.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    296. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev. 2011 Dec 15; 25(24):2559-72. Shiao SL, Ganesan AP, Rugo HS, Coussens LM. PMID: 22190457.
      View in: PubMed   Mentions: 137     Fields:    Translation:HumansAnimals
    297. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012 Feb 09; 366(6):520-9. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. PMID: 22149876.
      View in: PubMed   Mentions: 896     Fields:    Translation:HumansCTClinical Trials
    298. Current treatment options for metastatic breast cancer: what now? Clin Adv Hematol Oncol. 2011 Nov; 9(11 Suppl 25):1-16. Rugo HS, O'Shaughnessy JA, Perez EA. PMID: 22362269.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    299. Clinical roundtable monograph. Current treatment options for metastatic breast cancer: what now? Clin Adv Hematol Oncol. 2011 Nov; 9(11):1-16. Rugo HS, O'Shaughnessy JA, Perez EA. PMID: 22355830.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    300. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011 Nov 10; 29(32):4286-93. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. PMID: 21990397.
      View in: PubMed   Mentions: 135     Fields:    Translation:HumansCTClinical Trials
    301. Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment. Genome Med. 2011 Oct 04; 3(10):64. Lorizio W, Rugo H, Beattie MS, Tchu S, Melese T, Melisko M, Wu AH, Lawrence HJ, Nikoloff M, Ziv E. PMID: 21970596.
      View in: PubMed   Mentions: 4     Fields:    
    302. A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clin Cancer Res. 2011 Nov 01; 17(21):6897-904. Mayer EL, Baurain JF, Sparano J, Strauss L, Campone M, Fumoleau P, Rugo H, Awada A, Sy O, Llombart-Cussac A. PMID: 21903773.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    303. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2796-801. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. PMID: 21825174.
      View in: PubMed   Mentions: 160     Fields:    Translation:HumansCells
    304. New frontiers and treatment paradigms for metastatic breast cancer. A Review of an adjunct symposium of the 2011 American Society of Clinical Oncology Annual Meeting, June 4, 2011 Chicago, Illinois. Clin Adv Hematol Oncol. 2011 Aug; 9(8 Suppl 20):1-15. Perez EA, Mooberry S, Twelves C, Rugo HS. PMID: 22362034.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    305. Reducing the long-term effects of chemotherapy in young women with early-stage breast cancer. JAMA. 2011 Jul 20; 306(3):312-4. Rugo HS, Rosen MP. PMID: 21771995.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    306. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011 Jul 15; 17(14):4834-43. Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, Tudor IC, Wang LI, Brammer MG, Shing M, Yood MU, Yardley DA. PMID: 21768129.
      View in: PubMed   Mentions: 102     Fields:    Translation:Humans
    307. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011 Jun; 1(1):54-67. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL, Coussens LM. PMID: 22039576.
      View in: PubMed   Mentions: 673     Fields:    Translation:HumansAnimalsCells
    308. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol. 2011 Jun 20; 29(18):2459-65. Rugo HS, Stopeck AT, Joy AA, Chan S, Verma S, Lluch A, Liau KF, Kim S, Bycott P, Rosbrook B, Bair AH, Soulieres D. PMID: 21555686.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    309. Systemic treatment of early breast cancer--a biological perspective. J Surg Oncol. 2011 May 01; 103(6):619-26. Greenberg S, Stopeck A, Rugo HS. PMID: 21480257.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    310. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clin Cancer Res. 2011 May 15; 17(10):3398-407. McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, Gilewski T, Theodoulou M, Modi S, D'Andrea G, Sklarin N, Robson M, Moynahan ME, Sugarman S, Sealey JE, Laragh JH, Merali C, Norton L, Hudis CA, Dickler MN. PMID: 21350003.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    311. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res. 2011 Jan 15; 17(2):372-81. Jubb AM, Miller KD, Rugo HS, Harris AL, Chen D, Reimann JD, Cobleigh MA, Schmidt M, Langmuir VK, Hillan KJ, Chen DS, Koeppen H. PMID: 21224365.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    312. Bisphosphonates and their impact on disseminated tumor cells in early stage breast cancer. Breast Dis. 2011; 33(2):83-92. Li J, Rugo HS. PMID: 22142661.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    313. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011 Feb 01; 29(4):398-405. Burris HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA. PMID: 21172893.
      View in: PubMed   Mentions: 179     Fields:    Translation:HumansCTClinical Trials
    314. Cost comparison of capecitabine in patients with breast cancer. Am J Clin Oncol. 2010 Dec; 33(6):550-6. Rugo HS, Kohles J, Schulman KL. PMID: 20051811.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    315. Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer. Clin Breast Cancer. 2010 Dec 01; 10(6):421-39. Albain KS, Carey L, Gradishar WJ, Gralow JR, Lipton A, Rugo H, Tripathy D, Peck S, Abair T, Pegram M. PMID: 21147685.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    316. Studying cancer-related fatigue: report of the NCCN scientific research committee. J Natl Compr Canc Netw. 2010 Dec; 8(12):1331-9. Mortimer JE, Barsevick AM, Bennett CL, Berger AM, Cleeland C, DeVader SR, Escalante C, Gilreath J, Hurria A, Mendoza TR, Rugo HS. PMID: 21147900.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    317. Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer. Clin Breast Cancer. 2010 Sep; 10 Suppl 2:S20-9. Greenberg S, Rugo HS. PMID: 20805062.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    318. NCCN Clinical Practice Guidelines Cancer-related fatigue. J Natl Compr Canc Netw. 2010 Aug; 8(8):904-31. Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D, Cimprich B, Cleeland C, Eisenberger MA, Escalante CP, Jacobsen PB, Kaldor P, Ligibel JA, Murphy BA, O'Connor T, Pirl WF, Rodler E, Rugo HS, Thomas J, Wagner LI. PMID: 20870636.
      View in: PubMed   Mentions: 66     Fields:    Translation:Humans
    319. Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials. Clin Breast Cancer. 2010 Aug 01; 10(4):288-93. Rugo H, Brammer M, Zhang F, Lalla D. PMID: 20705561.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    320. Amelioration of sexual adverse effects in the early breast cancer patient. J Cancer Surviv. 2010 Sep; 4(3):247-55. Melisko ME, Goldman M, Rugo HS. PMID: 20602189.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    321. The cardiac safety of trastuzumab in the treatment of breast cancer. Expert Opin Drug Saf. 2010 Mar; 9(2):335-46. Chien AJ, Rugo HS. PMID: 20175700.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimals
    322. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010 Mar 01; 28(7):1124-30. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J. PMID: 20124187.
      View in: PubMed   Mentions: 281     Fields:    Translation:HumansCTClinical Trials
    323. Triple-negative breast cancer: role of antiangiogenic agents. Cancer J. 2010 Jan-Feb; 16(1):33-8. Greenberg S, Rugo HS. PMID: 20164688.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    324. Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol. 2010 Jan 01; 28(1):77-82. Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O'Brien P, Shepherd LE. PMID: 19901117.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    325. Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol. 2009 Dec 20; 27(36):6117-23. Morris PG, Dickler M, McArthur HL, Traina T, Sugarman S, Lin N, Moy B, Come S, Godfrey L, Nulsen B, Chen C, Steingart R, Rugo H, Norton L, Winer E, Hudis CA, Dang CT. PMID: 19901120.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    326. Implementing decision and communication aids to facilitate patient-centered care in breast cancer: a case study. Patient Educ Couns. 2009 Dec; 77(3):360-8. Belkora JK, Loth MK, Volz S, Rugo HS. PMID: 19850438.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    327. Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. J Clin Oncol. 2010 Feb 01; 28(4):628-33. Traina TA, Rugo HS, Caravelli JF, Patil S, Yeh B, Melisko ME, Park JW, Geneus S, Paulson M, Grothusen J, Seidman AD, Fornier M, Lake D, Dang C, Robson M, Theodoulou M, Flombaum CD, Norton L, Hudis CA, Dickler MN. PMID: 19841327.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    328. Special report: Consensus conference III. Image-detected breast cancer: state-of-the-art diagnosis and treatment. J Am Coll Surg. 2009 Oct; 209(4):504-20. Silverstein MJ, Recht A, Lagios MD, Bleiweiss IJ, Blumencranz PW, Gizienski T, Harms SE, Harness J, Jackman RJ, Klimberg VS, Kuske R, Levine GM, Linver MN, Rafferty EA, Rugo H, Schilling K, Tripathy D, Vicini FA, Whitworth PW, Willey SC. PMID: 19801324.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansPHPublic Health
    329. Antiemesis. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2009 May; 7(5):572-95. Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Markiewicz MA, Nabati L, Nesheiwat C, Rugo HS, Sorscher SM, Stucky-Marshal L, Todaro B, Urba S. PMID: 19460282.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    330. Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis. BMC Cancer. 2009 Apr 28; 9:127. Belkora JK, Rugo HS, Moore DH, Hutton DW, Chen DF, Esserman LJ. PMID: 19400938.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    331. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009 Jun 01; 27(16):2630-7. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS. PMID: 19380449.
      View in: PubMed   Mentions: 215     Fields:    Translation:HumansCellsCTClinical Trials
    332. A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemother Pharmacol. 2009 Nov; 64(6):1139-48. Rixe O, Franco SX, Yardley DA, Johnston SR, Martin M, Arun BK, Letrent SP, Rugo HS. PMID: 19294387.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    333. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer. Cancer Treat Res. 2009; 151:197-215. Jo Chien A, Rugo HS. PMID: 19593514.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    334. A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7878-83. Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton L, Hudis CA. PMID: 19047117.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    335. New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nat Clin Pract Oncol. 2009 Jan; 6(1):25-33. Melisko ME, Glantz M, Rugo HS. PMID: 18936791.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    336. Risk communication with patients with breast cancer: cautionary notes about printing Adjuvant! estimates. Lancet Oncol. 2008 Jul; 9(7):602-3. Belkora J, Rugo HS, Moore DH, Hutton D, Esserman L. PMID: 18598923.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    337. Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival. J Neurooncol. 2008 Jul; 88(3):359-65. Melisko ME, Moore DH, Sneed PK, De Franco J, Rugo HS. PMID: 18398574.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    338. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008 Apr 10; 26(11):1810-6. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD. PMID: 18347007.
      View in: PubMed   Mentions: 175     Fields:    Translation:HumansCTClinical Trials
    339. Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus roundtable. Clin Breast Cancer. 2008 Feb; 8(1):33-7. Gralow J, Rugo H, Gradishar W, O'Shaughnessy JA, Jahanzeb M, Perez E, Tripathy D. PMID: 18501057.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    340. The importance of distant metastases in hormone-sensitive breast cancer. Breast. 2008 Jan; 17 Suppl 1:S3-8. Rugo HS. PMID: 18279764.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    341. Quantitative and clinical description of postural instability in women with breast cancer treated with taxane chemotherapy. Arch Phys Med Rehabil. 2007 Aug; 88(8):1002-8. Wampler MA, Topp KS, Miaskowski C, Byl NN, Rugo HS, Hamel K. PMID: 17678662.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    342. Strategies for the prevention of treatment-related bone loss in women receiving adjuvant hormonal therapy. Clin Breast Cancer. 2007 Jul; 7 Suppl 1:S21-8. Rugo HS. PMID: 17683650.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    343. Acupressure for chemotherapy-induced nausea and vomiting: a randomized clinical trial. Oncol Nurs Forum. 2007 Jul; 34(4):813-20. Dibble SL, Luce J, Cooper BA, Israel J, Cohen M, Nussey B, Rugo H. PMID: 17723973.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    344. Hormonal therapy for advanced breast cancer. Hematol Oncol Clin North Am. 2007 Apr; 21(2):273-91. Rugo HS. PMID: 17512449.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    345. Bevacizumab for advanced breast cancer. Hematol Oncol Clin North Am. 2007 Apr; 21(2):303-19. Traina TA, Rugo HS, Dickler M. PMID: 17512451.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    346. The role of trastuzumab in early stage breast cancer: current data and treatment recommendations. Curr Treat Options Oncol. 2007 Feb; 8(1):47-60. Lin A, Rugo HS. PMID: 17660958.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    347. Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer. Breast Cancer Res Treat. 2007 Sep; 105(1):17-28. Rugo H, Shtivelman E, Perez A, Vogel C, Franco S, Tan Chiu E, Melisko M, Tagliaferri M, Cohen I, Shoemaker M, Tran Z, Tripathy D. PMID: 17111207.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    348. The role of angiogenesis inhibition in the treatment of breast cancer. Clin Adv Hematol Oncol. 2006 Oct; 4(10 Suppl 21):1-10; quiz 11-2. Sledge GW, Rugo HS, Burstein HJ. PMID: 17139244.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    349. Targeting growth factors and angiogenesis; using small molecules in malignancy. Cancer Metastasis Rev. 2006 Jun; 25(2):279-92. Wanebo HJ, Argiris A, Bergsland E, Agarwala S, Rugo H. PMID: 16770540.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    350. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. Biol Blood Marrow Transplant. 2006 Mar; 12(3):316-24. Damon L, Rugo H, Tolaney S, Navarro W, Martin T, Ries C, Case D, Ault K, Linker C. PMID: 16503501.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    351. Paclitaxel poliglumex. Cell Therapeutics/Chugai Pharmaceutical. IDrugs. 2005 Sep; 8(9):739-54. Man M, Rugo H. PMID: 16118697.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    352. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 2005 Aug 20; 23(24):5474-83. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G. PMID: 16027439.
      View in: PubMed   Mentions: 137     Fields:    Translation:HumansCTClinical Trials
    353. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol. 2005 Aug 20; 23(24):5464-73. Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD, Herbst RS. PMID: 16027440.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansCTClinical Trials
    354. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol. 2005 Jun; 184(6):1774-81. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM. PMID: 15908529.
      View in: PubMed   Mentions: 89     Fields:    Translation:Humans
    355. High-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell cancer. Am J Clin Oncol. 2005 Apr; 28(2):130-7. Chaudhary UB, Damon LE, Rugo HS, Linker CA, Navarro W, Small EJ. PMID: 15803005.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    356. Patient and physician attitudes toward breast cancer clinical trials: developing interventions based on understanding barriers. Clin Breast Cancer. 2005 Apr; 6(1):45-54. Melisko ME, Hassin F, Metzroth L, Moore DH, Brown B, Patel K, Rugo HS, Tripathy D. PMID: 15899072.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    357. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005 Feb 01; 23(4):792-9. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS. PMID: 15681523.
      View in: PubMed   Mentions: 311     Fields:    Translation:HumansCTClinical Trials
    358. Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation. J Am Coll Surg. 2004 Dec; 199(6):856-62. Lang JE, Esserman LJ, Ewing CA, Rugo HS, Lane KT, Leong SP, Hwang ES. PMID: 15555967.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    359. Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule. Cancer Chemother Pharmacol. 2004 Jun; 53(6):468-74. Damon LE, Johnston LJ, Ries CA, Rugo HS, Case D, Ault K, Linker CA. PMID: 15138711.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    360. Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist. 2004; 9 Suppl 1:43-9. Rugo HS. PMID: 15178815.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimals
    361. The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research. Semin Oncol. 2003 Dec; 30(6):749-62. Rugo HS, Ahles T. PMID: 14663776.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    362. Management of breast cancer diagnosed during pregnancy. Curr Treat Options Oncol. 2003 Apr; 4(2):165-73. Rugo HS. PMID: 12594943.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans